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ABSTRACT 
End-stage renal disease is an 
increasingly common pathologic condition, 
with a current incidence of 87 per million 
inhabitants in Finland. It is the end point of 
various nephropathies, most common of 
which is the diabetic nephropathy. This 
thesis focuses on exploring the role of 
nephrin in the pathogenesis of diabetic 
nephropathy. Nephrin is a protein of the 
glomerular epithelial cell, or podocyte, and it 
appears to have a crucial function as a 
component of the filtration slit diaphragm in 
the kidney glomeruli. Mutations in the 
nephrin gene NPHS1 lead to massive 
proteinuria. Along with the originally 
described location in the podocyte, nephrin 
has now been found to be expressed in the 
brain, testis, placenta and pancreatic beta 
cells. In type 1 diabetes, the fundamental 
pathologic event is the autoimmune 
destruction of the beta cells. Autoantibodies 
against various beta cell antigens are 
generated during this process. Due to the 
location of nephrin in the beta cell, we 
hypothesized that patients with type 1 
diabetes may present with nephrin 
autoantibodies. We also wanted to test 
whether such autoantibodies could be 
involved in the pathogenesis of diabetic 
nephropathy. 
The puromycin aminonucleoside 
nephrosis model in the rat, the streptozotocin 
model in the rat, and the non-obese diabetic 
mice were studied by immunochemical 
techniques, in situ –hybridization and the 
polymerase chain reaction –based methods 
to resolve the expression of nephrin mRNA 
and protein in experimental nephropathies. 
To test the effect of antiproteinuric 
therapies, streptozotocin-treated rats were 
also treated with aminoguanidine or 
perindopril. To detect nephrin antibodies we 
developed a radioimmunoprecipitation assay 
and analyzed follow-up material of 66 
patients with type 1 diabetes. 
In the puromycin aminonucleoside 
nephrosis model, the nephrin expression 
level was uniformly decreased together with 
the appearance of proteinuria. In the 
streptozotocin-treated rats and in non-obese 
diabetic mice, the nephrin mRNA and 
protein expression levels were seen to 
increase in the early stages of nephropathy. 
However, as observed in the streptozotocin 
rats, in prolonged diabetic nephropathy the 
expression level decreased. We also found 
out that treatment with perindopril could not 
only prevent proteinuria but also a decrease 
in nephrin expression in streptozotocin-
treated rats. Aminoguanidine did not have an 
effect on nephrin expression, although it 
could attenuate the proteinuria. 
Circulating antibodies to nephrin in 
patients with type 1 diabetes were found, 
although there was no correlation with the 
development of diabetic nephropathy. At 
diagnosis, 24% of the patients had these 
antibodies, while at 2, 5 and 10 years of 
disease duration the respective proportions 
were 23%, 14% and 18%. During the total 
follow-up of 16 to 19 years after diagnosis 
of diabetes, 14 patients had signs of 
nephropathy and 29% of them tested 
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positive for nephrin autoantibodies in at least 
one sample. 
In conclusion, this thesis work could 
show changes of nephrin expression along 
with the development of proteinuria. The 
autoantibodies against nephrin are likely 
generated in the autoimmune process 
leading to type 1 diabetes. However, 
according to the present work it is unlikely 
that these autoantibodies are contributing 
significantly to the development of diabetic 
nephropathy. 
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1 INTRODUCTION 
The discovery of nephrin in 1998 
(Kestilä M et al., 1998) opened a window on 
our understanding of the structure and 
function of the slit diaphragm in greater 
detail than before. Nephrin was apparently a 
protein expressed specifically in the 
podocytes of the kidney glomeruli. Since the 
absence of nephrin in the congenital 
nephrotic syndrome of the Finnish type 
results in massive proteinuria, nephrin was 
obviously a crucial component of the slit 
diaphragm. Proteinuria is a hallmark of 
nephropathies, including diabetic 
nephropathy. The present study was 
motivated by the need to enhance our 
understanding on the basic underlying 
pathological processes of proteinuria 
involving the podocyte. To begin exploring 
the nephrin behaviour in experimental 
proteinuria, we chose to study the 
puromycin aminonucleoside nephrosis 
model in the rat which resembles the human 
minimal change nephropathy and presents 
with transient, massive proteinuria. 
Thereafter the diabetic nephropathy was 
studied using the streptozotocin model in the 
rat and non-obese diabetic mice. 
Nephrin was soon shown to be 
localized in the pancreatic beta cells (Palmen 
T et al., 2001). While little is still known of 
the specific functions of nephrin in the beta 
cells, a variety of beta cell epitopes are 
known to act as autoantigens in diabetes 
(Palmer JP et al., 1983; Baekkeskov S et al., 
1990; Lan MS et al., 1996). This new 
information with the interesting report that 
experimentally administered nephrin 
antibodies cause a massive proteinuria 
(Topham PS et al., 1999) led us to 
hypothesize that nephrin may also act as an 
autoantigen in type 1 diabetes. To resolve 
this issue, we developed an appropriate 
radioimmunoprecipitation assay and 
analyzed well-characterized follow-up 
material of patients with type 1 diabetes. 
Furthermore, we wanted to find out whether 
the presence of nephrin autoantibodies could 
influence the development of diabetic 
nephropathy. 
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2 REVIEW OF THE LITERATURE 
2.1 Structure and function of the kidney 
2.1.1 Kidney in overview 
In the kidneys (Figure 2.1.1A), blood 
is filtered through the capillaries in the 
glomerulus to form a primary filtrate 
resembling blood plasma. This filtrate then 
passes through a tubular system, in which 
the processes of tubular reabsorption and 
tubular secretion take place. The resulting 
final urine is a concentrate of waste 
metabolites, whilst water, important proteins 
or metabolites such as glucose and necessary 
electrolytes are efficiently conserved. 
Normal urine contains only minute amounts 
of protein, mainly shed or secreted from 
tubular cells (Ganong WF, 2003b). 
2.1.2 The nephron 
The functional unit in the kidney is 
the nephron (Figure 2.1.1B). There are 
approximately 0.7 million nephrons in each 
human kidney, although great individual 
variation, associated mainly with 
birthweight, occurs (Hughson M et al., 
2003). Each nephron consists of a tuft of 
capillary loops, or the glomerulus, and a 
tubular system, as illustrated in Figure 
2.1.1B. Glomerulus is a structure of thin 
capillary loops in the kidney cortex. The 
glomeruli are responsible for the primary 
filtration of plasma in the process of urine 
formation. The tubular system allows the 
reabsorption of water and electrolytes, which 
mainly takes place in the loop of Henle. 
There is also a hormonally regulated 
mechanism to adjust the release of water 
into urine in the distal part of the tubular 
system and collecting duct. The blood flow 
to the glomerulus is supplied by the afferent 
arteriole, while an efferent arteriole drains 
the glomerular capillaries. The efferent 
arteriole then divides again into multiple 
capillaries to form a capillary network, 
which surrounds the tubules. Some of these 
capillaries, called the vasa recta, also dip to 
the medulla of the kidney alongside with the 
loops of Henle. This medullary capillary 
plexus and the specialized endothelium in 
these vessels facilitate the reabsorption of 
water from the tubules to the capillary 
network (Ganong WF, 2003b). 
2.1.3 Nephrogenesis 
Nephrogenesis begins at a phase in 
the development where two tissues of 
different embryologic origins exist: the 
metanephric mesenchymal blastema and the
 
Figure 2.1.1. This illustration displays the anatomy of a coronally cut left kidney (A), the nephron 
and its associated vasculature (B), a schematic representation of the glomerulus (C), and a view of 
podocyte foot processes surrounding a glomerular capillary (D). Drawn after Ganong WF (2003b), 
Gartner LP et al. (1997a) and Netter FH (1997). 
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ureteric bud arising from the Wolffian duct. 
The ureteric bud is induced by the 
mesenchymal cells to grow and branch into 
the blastema at weeks 8-9 in human 
embryonal development. As depicted in 
Figure 2.1.2, in a series of interactions 
between these two tissues, the mesenchymal 
cells condense to the tip of the branching 
ureteric bud (A-C), convert into epithelial 
cells (D), form a comma-shaped body (E), 
an S-shaped body (F), and then differentiate 
into specialized epithelial cell types. 
Subsequently, capillary vessels grow into the 
lower cleft of the S-shaped body (G) and the 
glomerulus forms (H). The distal part of the 
S-shaped body is also elongated to form the 
tubular part of the nephron. Finally, the cells 
of the mesenchymal blastema have formed 
the epithelium from the glomerulus until the 
distal tubulus, and the ureteric bud has 
formed the collecting duct system and its 
branches (Horster M et al., 1997).
 
 
Figure 2.1.2. Development of the nephron from the ureteric bud to the formation of the 
glomerulus. See text for further details. Modified from Horster M et al., 1997. 
2.1.4 Glomerulus 
Glomerulus is a tight tuft of capillary 
loops, surrounded by the visceral glomerular 
epithelial cells, or podocytes, and their foot 
processes. This structure is surrounded by 
the Bowman’s capsule made up of the 
parietal glomerular epithelial cells, which 
direct the primary urine to the tubular 
system. A more detailed view of the 
glomerular filtration barrier shows that there 
is a finely composed structure responsible 
for the primary filtration of plasma (Figures 
2.1.1C and D). Between the blood flowing in 
the capillaries of a glomerulus and the 
urinary space are a fenestrated endothelium, 
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a specialized glomerular basement 
membrane (GBM) and the glomerular 
visceral epithelial cell layer, the podocytes 
(Gartner LP et al., 1997a). Mesangial cells 
are located between the capillary loops. 
They keep the capillary tuft together and 
secrete various substances essential to the 
function of the glomerular filter, e.g. 
components of the basement membrane, 
addressed later on in this review in chapter 
2.5. The filtration function of the kidney is 
often measured by the glomerular filtration 
rate (GFR), which is defined as the volume 
of fluid filtered from the blood in renal 
glomerular capillaries into the urinary space 
in Bowman's capsule per unit of time. 
Mesangial cells also have contractile 
properties to regulate the GFR by altering 
the tension around the glomerular capillaries 
(Stockand JD et al., 1998). The fenestrated 
capillary endothelium has pores with a 
diameter of 70-90 nm and allows even fairly 
large proteins to reach the underlying 
basement membrane. The pores are rimmed 
with anionic glycoproteins and lipids 
(Hjalmarsson C et al., 2004). However, not 
all of the molecules reaching the 300 nm 
thick basement membrane are allowed to 
pass through due to its anionic charge and 
dense structure (Ganong WF, 2003b). The 
main constituents of the GBM are type IV 
collagen and laminin, while large-sized 
heparan sulphate proteoglycans such as 
agrin and perlecan as well as fibronectin and 
nidogen are also components of this 
structure (Miner JH, 2003). The podocytes 
and their interdigitating foot processes 
surround the loops of capillary vessels from 
all exposed aspects. Between the foot 
processes is left a thin space of 
approximately 25 nm bridged by a slit-like 
membrane called the filtration slit 
diaphragm (Figure 2.1.1D). The forming 
filtrate must also pass the filtration slits, 
which further hinders the passage of larger 
proteins. Alternatively, proteins may also be 
passed actively through the cells in the 
filtration barrier in a process called 
transcytosis (Tischer CC et al., 1991). 
Ultimately, the filtration system as a whole 
effectively excludes the passage of 
substances larger than 8 nm in diameter. 
However, negatively charged molecules are 
repelled by the rims of the endothelial pores 
and the basement membrane so that filtration 
of anionic substances of 4 nm in diameter is 
only half of neutral substances of 
comparable size (Ganong WF, 2003b). 
In recent years, several structural-
functional proteins of the filtration slit 
membrane have been discovered. The best 
known structural protein is nephrin. The 
gene encoding nephrin, NPHS1, was found 
in 1998 (Kestilä M et al., 1998). This 
discovery was the result of longstanding 
research on the genetic background of the 
congenital nephrotic syndrome of the 
Finnish type (CNF), a condition leading to 
massive proteinuria already in utero. In 
CNF, mutations of the gene NPHS1 lead to 
truncation of protein synthesis and absence 
of functional nephrin (Lenkkeri U et al., 
1999). This was a demonstration of the 
crucial role of the filtration slit in 
maintaining the function of the glomerular 
filtration barrier. Intensive research on other 
podocyte proteins contributing to the 
integrity of the filtration slit membrane 
ensued. Presently, such known proteins 
associated to nephrin and filtration slit are 
the Neph-proteins, podocin, CD2-associated 
protein (CD2AP), FAT, densin, and P-
cadherin. Also podocalyxin and various 
other proteins are important in the podocyte 
function. These proteins and their 
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interactions are discussed further in chapter 
2.6. 
2.1.5 Tubulus 
The tubular system consists of the 
proximal tubule, the loop of Henle, and the 
distal tubule (Figure 2.1.1.B). The proximal 
tubule begins from the Bowman’s capsule 
surrounding the glomerulus. As the proximal 
tubule is highly convoluted near the 
glomerulus this most proximal segment is 
known as the pars convoluta. The more 
distal portion of the proximal tubule is 
straighter, known as the pars recta. The pars 
recta may also be called the descending 
thick limb of Henle’s loop. It descends 
towards the medulla to become continuous 
with the thin limb of Henle’s loop. About 
80% of sodium, chloride, and water, as well 
as main part of the glucose, free amino acids 
and protein in the glomerular primary filtrate 
are normally resorbed by the cuboidal 
epithelial cells of the proximal tubule 
(Gartner LP et al., 1997a). 
The thin limb of Henle’s loop is 
composed of squamous epithelial cells, and 
its descending part is highly permeable to 
water, as well as to urea, sodium, chloride 
and other ions. The ascending part of the 
thin limb is only moderately permeable to 
water. This difference in water permeability 
is important in the reabsorption of water into 
the capillary vessels (Gartner LP et al., 
1997a). However, the greater details of the 
countercurrent multiplier and exchange 
mechanisms are beyond the scope of this 
review, but are found in the review by 
Ganong WF, 2003b. 
The distal tubule begins with pars 
recta, also known as the ascending thick 
limb of Henle’s loop, and continues as the 
distal convoluted tubule (pars convoluta). 
The distal tubule is impermeable to water 
and urea, so that the urea concentration in 
the tubular lumen remains high. The cells of 
pars convoluta have Na+-K+ ATPase pumps, 
which in response to the hormone 
aldosterone can actively resorb all of the 
remaining sodium from the lumen of the 
tubule (Gartner LP et al., 1997a). 
The tubular system and the interstitial 
kidney tissue are typically damaged in 
conditions with chronic proteinuria and 
glomerular scarring. Because the tubules are 
perfused by the capillary vessels arising 
from glomerular efferent arterioles (Figure 
2.1.1.B), advanced glomerulosclerosis leads 
to tubular ischemia and interstitial fibrosis. 
Thus, nephrosclerosis involving the entire 
organ may be the result of long-standing 
diabetes (Kumar V et al., 1992). 
2.2 The endocrine pancreas – structural and functional review 
2.2.1 Overview of the pancreas 
The pancreas has exocrine and 
endocrine functions. The largest portion of 
the pancreatic tissue consists of the exocrine 
acinar cells, which occupy about 80% of the 
total volume of the gland. These cells 
excrete various digestive enzymes via the 
pancreatic duct into the duodenum, 
including amylase, lipase, ribonuclease, 
DNase, and the proenzymes trypsinogen, 
chymotrypsinogen, procarboxypeptidase, 
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and elastase. Only 2-4% of the pancreatic 
tissue consists of cells with endocrine 
function, while mainly ducts and blood 
vessels take the rest of the space. The 
endocrine activity is scattered to the 1-2 
million islets of Langerhans, which are 
approximately 75x175 µm sized oval 
collections of about 3000 cells surrounded 
by pancreatic acinar cells. The islets are 
penetrated by a network of capillaries. Each 
islet of Langerhans contains at least five cell 
types: α-cells, β-cells, δ-cells, G cells and F 
cells (Gartner LP et al., 1997b). 
2.2.2 Development of the pancreas 
The pancreas is initially derived from 
separate endodermal dorsal and ventral buds 
arising from the so-called foregut at week 
four of embryonic development in human. 
Later these buds form the main ducts of 
pancreas (Johansson KA et al., 2002). The 
dorsal bud develops from just below the 
notochord in the region of the stomach. The 
ventral pancreas, originally formed adjacent 
to the liver, rotates to the left and eventually 
comes into contact with the dorsal bud by 
the beginning of week six. The ducts inside 
each part interconnect, elongate and branch. 
The terminal parts of the ducts form the 
exocrine acini and cell clumps migrate away 
from the walls of smaller branches into the 
surrounding mesenchyme to give rise to the 
endocrine islets. The precursory islets then 
expand through proliferation and by merging 
with other nearby cell clumps. Cells begin to 
differentiate into specialized islet cell 
populations after gestational week 10. 
Angiogenesis begins in the mesenchyme and 
by week 13 the islets have a fine capillary 
network. Finally, at week 17 the beta cells 
begin to excrete insulin. For a review, see 
Johansson KA et al., 2002. 
2.2.3 Beta cells and other islet cells 
Beta cells are the most common cell 
type in the islets, occupying an estimated 
proportion of 60-80% of the islet cells 
(Gartner LP et al., 1997b). They produce 
insulin and accumulate it into cytoplasmic 
granules to await regulated excretion. Insulin 
is encoded in the human by a single gene, 
INS, at chromosomal location 11p15.5 
(Harper ME et al., 1981). In the rat and 
mouse insulin is encoded by two genes with 
essentially identical protein products 
(Lomedico P et al., 1979; Wentworth BM et 
al., 1986). In the human, insulin is 
synthesized first as a preproinsulin at the 
rough endoplasmic reticulum. Insulin is 
directed into the endoplasmic reticulum and 
thus to its regulated exocytic pathway by a 
signalling polypeptide fragment, which is 
cotranslationally cleaved off to yield 
proinsulin (Eskridge EM et al., 1986). At the 
trans-Golgi network, proinsulin is packed 
into vesicles coated with the common 
packaging-molecule clathrin. A segment of 
the proinsulin known as the C-peptide is 
then removed by the endoproteases 
prohormone convertase 1/3 and 2 (Arvan P 
et al., 2004). The vesicles then mature and 
lose their clathrin coat and present finally as 
the intracellular granules containing insulin. 
As the beta cell adenoside triphosphate 
(ATP) level increases, most commonly due 
to increased blood glucose level, the ATP-
sensitive K+ channels on the cell membrane 
are closed, the beta cell depolarizes and 
exocytoses its insulin. Insulin then diffuses 
through the basal lamina to the adjacent 
fenestrated capillaries and is carried via the 
bloodstream to the hepatic portal vein and 
further to the systemic circulation. 
Interestingly, nephrin has been found in the 
islets of Langerhans. It has been reported to 
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be localized on the beta cells (Palmen T et 
al., 2001) and/or the endothelium of the 
capillaries in the islets (Zanone MM et al., 
2005). 
Insulin acts on specific target cells 
which express insulin receptors. The effects 
of insulin are mediated by the insulin 
receptors and their intracellular ligands, the 
insulin receptor subtrates 1 and 2, which are 
located in nearly all cells. In the tissues, 
especially in skeletal muscle, liver and 
adipose tissue, insulin has the important and 
immediate function to increase glucose entry 
into cells. Binding of insulin to its receptors 
causes a rapid translocation of facilitative 
glucose transport molecules to the cell 
membrane, which allow an increased flux of 
glucose into the cell (Ganong WF, 2003c). 
Activation of insulin signalling increases 
amino acid and potassium entry into insulin-
sensitive cells. Insulin also reduces 
gluconeogenesis and glucose release by the 
liver, stimulates protein synthesis and 
increases lipogenesis in adipose tissue. With 
special reference to the kidney it has been 
recently shown that insulin also has direct 
effects on the podocyte as well (Coward RJ 
et al., 2005b). According to the latest 
communicated results, nephrin seems to be 
crucial for the function of insulin in the 
podocyte (Coward RJ et al., 2005a). 
The alpha cells of the islets of 
Langerhans secrete glucagon, a peptide 
hormone released in response to low blood 
glucose levels (Gartner LP et al., 1997b). 
The main target of glucagon is the liver, 
where it acts on the hepatocytes causing 
them to rapidly break down their glycogen 
stores and release glucose to the 
bloodstream. Delta cells secrete 
somatostatin, which inhibits the endocrine 
activity of the alpha and beta cells. Further, 
somatostatin reduces motility of the 
gastrointestinal tract and gallbladder. 
Somatostatin is released after the digestion 
of a meal in response to increased blood 
levels of amino acids, glucose or 
chylomicrons. G cells release and produce 
gastrin, a hormone stimulating gastric 
motility, release of HCl and regeneration of 
gastric wall cells. The F cells secrete 
pancreatic polypeptide (PP) and are 
therefore also known as the PP cells. 
Pancreatic polypeptide inhibits the exocrine 
secretions of the pancreas (Gartner LP et al., 
1997b). 
2.3 Type 1 diabetes 
2.3.1 Epidemiology 
In Finland, the current incidence of 
type I diabetes is approximately 54 per 
100000 in children under 15 years of age 
(Knip M et al., 2005), which is the highest in 
the world. The incidence has been increasing 
constantly at a mean annual rate of 3% 
(Onkamo P et al., 1999). The lower end of 
the incidence scale includes China and 
Venezuela, where the incidence rates are at 
0.1 per 100000 (Karvonen M et al., 2000), 
representing a more than 500-fold variation 
among the world population. It is also 
possible that the onset of this disease is now 
occurring at an earlier age than before 
(Karvonen M et al., 1999). The increase in 
the incidence of as well as the new research 
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on the genetic background of type 1 diabetes 
suggests that a yet unknown and increasing 
environmental factor triggers the disease in 
some of genetically susceptible individuals. 
2.3.2 Pathogenesis 
Type 1 diabetes is a disease caused 
by autoimmunity. The central pathologic 
event is the triggering of immunological 
destruction of pancreatic beta cells in the 
islets of Langerhans. Before the onset of 
clinical symptoms and almost a total lack of 
insulin, there is a phase of varied duration 
with decreasing insulin secretion. The 
respective gradual destruction of beta cells is 
primarily mediated by the T-cells of the 
immune system, and T-cell infiltration is 
histologically visible in the early prediabetic 
phase of the disease (Bottazzo GF et al., 
1985). Inflammation of the pancreatic islets, 
insulitis, is preceded by the loss of 
immunological tolerance towards products 
of beta cells, mainly insulin. The exact 
mechanism leading to this loss of 
immunotolerance is not known, although the 
central role of autoreactive T-cells (Roep 
BO, 2003) and particularly the regulatory T-
cells (Lan RY et al., 2005) is acknowledged. 
A pathogenetic model proposes that in 
genetically susceptible individuals a 
triggering exogenous factor commences the 
autoimmunity against beta cells, driven by 
another environmental antigen, and modified 
by various environmental factors (Knip M et 
al., 2005). 
During the initial stages of the 
disease process, the humoral part of the 
immune system is also activated. This leads 
to development of circulating antibodies to 
various “self” antigens. The most important 
autoantibodies are the glutamic acid 
decarboxylase autoantibodies (GADA) 
(Baekkeskov S et al., 1990), islet antigen 2 
autoantibodies (IA-2A; Lan MS et al., 1996) 
and insulin autoantibodies (IAA; Palmer JP 
et al., 1983). The presence of these 
autoantibodies is a sign of activation of the 
autoimmune process and their detection is of 
clinical use in predicting the onset of 
diabetes in subjects at risk, e.g. siblings of a 
type 1 diabetic patient. 
2.3.3 Genetic and other risk factors 
Genetic predisposition is known to be 
important for the development of type 1 
diabetes (OMIM: 222100). In siblings of a 
type 1 diabetic patient the average risk for 
developing the disease is 6-7% (Harjutsalo 
V et al., 2005). In monozygotic twins with 
identical genetic configuration the 
concordance for type 1 diabetes is 30-50% 
(Kyvik KO et al., 1995; Hyttinen V et al., 
2003). 
The best characterized genetic factor 
is the human leukocyte antigen (HLA) gene 
complex located on the short arm of the 
chromosome 6 at the band p21.3. The genes 
within the HLA gene complex are known to 
explain up to 50% of the genetic component 
of risk for type 1 diabetes (Vyse TJ et al., 
1996). The HLA genes are generally divided 
into three classes: class I genes (A, B, C and 
others) encode proteins expressed in all 
nucleated cells and present peptide 
fragments derived from cytosolically 
produced proteins (endogenous pathway of 
antigen presentation) to CD8+ (cytotoxic) T 
cells; class II genes (DP, DQ, DR and 
others) encode heterodimeric membrane 
proteins expressed in specific antigen-
presenting cells (e.g. activated T cells, B 
cells, dendritic cells, macrophages) and they 
are involved in the presentation of 
exogenously derived peptides to the CD4+ 
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(helper) T cells; class III genes contain 
various genes of the complement system and 
some cytokines (Kelly MA et al., 2003). 
Earlier serologic identification of HLA 
antigens in individuals was used, and the 
antigens were grouped accordingly to 
various HLA-serotypes e.g. DR1, DR2, 
DQ1, DQ2, and so on (Schwartz BD, 1987). 
In the more recent era of genetics, it has 
become possible to identify much more 
detailed differences in the genes encoding 
the HLA antigens. Today, numerous alleles 
of HLA genes are known among each 
serologically defined, broad antigen group. 
A nomenclature committee under the World 
Health Organization agrees on the naming 
conventions of these alleles. Briefly, their 
current naming convention first describes 
the gene locus followed by an asterisk and a 
series of 4 to 8 digits corresponding to the 
serologic allele family (2 digits), and the 
allele coding variation (2 digits). The last 4 
digits and specific letter suffices are 
sometimes used for separating further 
variation (Marsh SG et al., 2002). 
In particular, the genes DQB1, DQA1 
and DRB1 in the HLA class II are 
determinants of type 1 diabetes risk. Strong 
linkage disequilibrium, i.e. the inheritance of 
alleles at distinct loci together more 
frequently than expected by chance, is 
present between many genes in the HLA 
complex, making it difficult to identify the 
primary susceptibility determinants of type 1 
diabetes (Kelly MA et al., 2003). According 
to current knowledge, susceptibility is 
associated with two combinations of DQA1 
and DQB1 alleles: DQA1*0301-
DQB1*0302 (encoding protein HLA-DQ8) 
and DQA1*0501-DQB1*0201 (encoding 
protein HLA-DQ2), while other 
combinations such as DQA1*0102-
DQB1*0602 (encoding protein HLA-
DQ6.2) carry a protective effect. Also, two 
allele families of DRB1 associate with type 
1 diabetes risk, the DRB1*04 and the 
DRB1*03, encoding proteins DR4 and DR3, 
respectively. Linkage disequilibrium 
between the DRB1*03 and DQA1*0501-
DQB1*0201 allele combination forms the 
predisposing haplotype DR3-DQ2.  Another 
such linkage between the alleles DRB1*04 
and DQA1*0301-DQB1*0302 forms the 
predisposing haplotype DR4-DQ8 (Kelly 
MA et al., 2003). Accordingly, the highest 
genetic risk is conferred by the heterozygous 
DR3-DQ2/DR4-DQ8 genotype (Ilonen J et 
al., 2002). Up to 90% of patients with type 1 
diabetes carry at least one of the above 
mentioned predisposing haplotypes, while in 
other patients susceptibility is carried by 
other HLA haplotypes (Undlien DE et al., 
1999). 
The research today has proceeded 
beyond the study of HLA alleles and is 
focusing on the search for other genetic 
factors predisposing to type 1 diabetes. More 
than 20 candidate loci have been proposed 
but only three of them are reliably 
characterized and confirmed. Discussed 
below, these genes are the INS-VNTR, the 
CTLA-4 and the PTPN22. 
In 1984, Bell et al. reported a region 
near the insulin gene at 11p15 with a 
variable number of tandemly repeated 
(VNTR) 14-bp oligonucleotides (Bell GI et 
al., 1984). Furthermore this minisatellite 
locus upstream of the insulin gene is 
suggested to influence the messenger 
ribonucleic acid (mRNA) expression of 
insulin and insulin-like growth factor 2 
genes in the thymus and pancreas (Pugliese 
A et al., 1997; Vafiadis P et al., 1997), 
which is shown to affect the T cell self-
tolerance (Anjos S et al., 2004). Depending 
on the type of the VNTR-sequence it could 
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increase or decrease self-tolerance (Bennett 
ST et al., 1995), although the exact 
molecular mechanisms predisposing to type 
1 diabetes are not yet clear. 
The cytotoxic T-lymphocyte antigen 
4 (CTLA-4) is a transmembrane protein of 
CD4+ T cells normally taking part in the 
elimination of self-reactive T cells. Multiple 
studies have confirmed its association with 
type 1 diabetes (Nistico L et al., 1996; 
Kavvoura FK et al., 2005). The mechanism 
proposed to mediate the risk for type 1 
diabetes is a single nucleotide polymorphism 
in the signal peptide of CTLA-4 believed to 
reduce the expression of this protein on the 
cell surface of T cells (Abbas AK et al., 
2004). 
The gene PTPN22 encodes the 
lymphoid protein tyrosine phosphatase 
(LYP), which is another T-cell activation 
suppressor. Originally described in 2004 
(Bottini N et al., 2004), the strong 
association of a single-nucleotide 
polymorphism in this gene with the risk for 
type 1 diabetes has already been confirmed 
by several studies (Onengut-Gumuscu S et 
al., 2004; Ladner MB et al., 2005; Zheng W 
et al., 2005). 
The known inherited risk factors 
leave a broad space for environmental 
factors as well, since not all of the 
genetically susceptible individuals develop 
type 1 diabetes. The exact exogenous 
triggering mechanism of the autoimmune 
event leading to destruction of insulin-
producing beta cells has not been established 
conclusively. However, it is believed that 
certain viral agents such as enterovirus 
infections could act as the triggering factor 
initiating autoimmunity, while dietary 
proteins such as cow milk proteins and 
particularly bovine insulin are speculated to 
be the driving antigens maintaining the 
process (Knip M et al., 2005). In conclusion, 
type 1 diabetes is a complex disease with 
multiple different gene loci and 
environmental factors involved in its 
pathogenesis. 
2.3.4 Clinical course and complications 
Most of the patients with type 1 
diabetes are under 20 years of age, whilst 
onset takes place later in a third of cases. 
Symptoms referring to type 1 diabetes are 
loss of weight, nausea, fatigue, abdominal 
pain, polydipsia, polyphagia, and polyuria 
(Williams G et al., 1994). The onset of 
symptoms may be abrupt and ketoacidosis is 
common. The only feasible treatment is 
insulin, which is administered 
subcutaneously. The majority of patients 
require multiple injection therapy consisting 
of a long-acting insulin and short-acting 
insulin injections at meals. The aim of the 
therapy is to maintain a physiologic level of 
blood glucose. To achieve this the glycated 
haemoglobin level reflecting the mean blood 
glucose levels of the last 3-4 months is 
measured regularly. Failure in maintaining 
good glycemic balance is a risk for 
developing complications. As a fundamental 
metabolic disorder, type 1 diabetes has 
serious complications affecting mainly the 
vascular system. The complications are 
generally divided into macro- and 
microvascular complications. An increased 
rate of atherosclerosis in the large vessels, 
foot ulcers possibly leading to amputation, 
and a high risk for coronary angiopathy are 
the macrovascular complications, whereas 
neuropathy, retinopathy and nephropathy are 
the distinct microvascular complications. 
Untreated retinopathy may eventually lead 
to blindness, whilst nephropathy is an 
important complication of diabetes as well. 
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Diabetic nephropathy is a pathologic process 
presenting first as an increasing loss of 
protein into the urine, while the ultimate 
weakening of the GFR leads to end-stage 
renal disease (ESRD) with retention of 
protein and waste metabolites. Diabetic 
nephropathy is the most common cause of 
ESRD in Finland and elsewhere in the world 
(United Kingdom Renal Registry, 2003; 
United States Renal Data System, 2003; 
Finnish Registry for Kidney Diseases, 
2005). In Finland, the incidence of ESRD 
resulting of diabetic nephropathy in 2004 
was approximately 33 per million 
inhabitants, explaining almost 40% of all 
new cases of ESRD (Finnish Registry for 
Kidney Diseases, 2005). This is largely due 
to the increased incidence of type 2 diabetes. 
Patients with diabetic nephropathy 
are treated with angiotensin converting 
enzyme (ACE) inhibitors, as they seem to 
have a renoprotective effect independent of 
the blood pressure lowering effect (Lewis EJ 
et al., 1993). Maintaining strict glycemic 
balance and blood pressure control, avoiding 
smoking, and, after the onset of proteinuria, 
applying a low-protein diet are other 
measures aiming to prevent or ameliorate the 
kidney complication. Dialysis and kidney 
transplantation remain as the only 
therapeutic options at end-stage renal 
disease. Approximately one third of patients 
with type 1 diabetes develop renal 
complications during the course of their 
disease, while some patients avoid 
nephropathy even where there is poor 
glycemic balance or other risk factors such 
as smoking (Rossing P et al., 1995; Rossing 
P et al., 2002; Hovind P et al., 2004). This 
suggests an important role for genetic 
predisposition, which is more 
comprehensively addressed in chapter 2.5. 
The incidence of diabetic nephropathy has 
been reported to decrease after the 
application of various modern therapeutic 
interventions (Bojestig M et al., 1994; 
Hovind P et al., 2003; Nordwall M et al., 
2004), although many studies have 
announced an unchanged incidence (Rossing 
P et al., 1995; Esmatjes E et al., 2002; 
Tryggvason G et al., 2005) or inadequacy of 
modern therapy to prevent the complication 
(Svensson M et al., 2003). After all, 
regardless of the underlying pathogenesis, 
all types of diabetes lead to increased blood 
glucose concentrations. This is considered to 
be an important factor in the complications 
of all types of diabetes, although other 
individual and environmental factors clearly 
contribute to the development of diabetic 
complications. 
2.3.5 Other types of diabetes 
The most common type of diabetes is 
the type 2 diabetes. In this form of the 
disease, insulin secretion defect is not the 
primary pathogenic mechanism. Instead, the 
function of insulin on target cells is reduced. 
Also other types of diabetes exist. One of 
them is the maturity-onset diabetes of the 
young (MODY), where very young patients 
present with symptoms similar to type 2 
diabetes. It is inherited in an autosomal 
dominant pattern (OMIM: 125850), and 
several associated genetic defects are 
known. Gestational diabetes is a transient 
decrease in glucose tolerance during 
pregnancy, although it involves an increased 
risk for developing type 2 diabetes later. The 
latent autoimmune diabetes in adults 
(LADA) is a type of diabetes with late-onset 
autoimmune destruction of pancreatic beta 
cells. Rare mitochondrial defects can also be 
a cause of diabetes. The common types of 
diabetes are also intermixing and the 
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metabolic syndrome behind the development 
of type 2 diabetes is fairly common in 
patients with type 1 diabetes as well. Up to 
40% of type 1 diabetic patients have 
metabolic syndrome (Thorn LM et al., 
2005). Furthermore, familial clustering of 
type 1 and type 2 diabetes is clear, with an 
increased frequency of type 2 diabetes in 
families with type 1 diabetes (Dahlquist G et 
al., 1989) and vice versa (Li H et al., 2001). 
2.4 Relevant animal models of renal disease 
2.4.1 Puromycin aminonucleoside 
nephrosis 
The puromycin aminonucleoside 
nephrosis (PAN) in the rat is a commonly 
used animal model for proteinuria. It is 
induced by a single intravenous injection of 
puromycin aminonucleoside. It is an 
antibiotic with antineoplastic properties and 
it can cause nephrosis. Thus, in the rat the 
injection leads to proteinuria at around day 
3, while the maximal effect is usually seen at 
day 10 (Ryan GB et al., 1975). After this, 
the condition is reversed so that normal 
kidney function is regained at around day 28 
(Ryan GB et al., 1975). The morphological 
and functional changes resemble the human 
minimal change nephropathy (Vernier RL et 
al., 1959). Morphological changes in the 
PAN model include dilation of tubuli, fusion 
of podocyte foot processes, alteration of the 
slit diaphragm and even replacement of the 
slit diaphragm by occluding-type junctions 
(Caulfield JP et al., 1976). At later stage, a 
characteristic detachment of podocytes is 
seen, allowing contact of the GBM with the 
urinary space (Messina A et al., 1987). The 
detailed mechanisms in which puromycin 
aminonucleoside induces nephrosis are not 
known. However, treatment with puromycin 
aminonucleoside of cultured podocytes 
resulted in impaired adhesion of these cells 
to type IV collagen and decreased 
expression of α3β1-integrin, the major 
integrin attaching the podocytes to the GBM 
(Krishnamurti U et al., 2001). Another in 
vitro study implicates apoptosis via 
oxidative stress in the detachment of 
podocytes from culture substrata (Suzuki T 
et al., 2001). 
2.4.2 Animal models of type 1 diabetes 
2.4.2.1 Streptozotocin model 
Streptozotocin (STZ) is a toxic 
nitrosurea derivative first isolated from 
Streptomyces achromogenes (Lewis C et al., 
1959; Vavra JJ et al., 1959). STZ has 
powerful alkylating capabilities and it 
induces multiple deoxyribonucleic acid 
(DNA) strand breaks in cells by direct 
methylation of DNA (Bennett RA et al., 
1981). In an animal model a single dose of 
STZ is given and diabetes develops usually 
in 1-2 days due to destruction of pancreatic 
beta cells (Rakieten N et al., 1963). STZ has 
the ability to efficiently destruct pancreatic 
beta cells because it is transported to the beta 
cell by the cell-surface glucose transporter 
GLUT-2. There are several glucose 
transporter protein types in various tissues, 
but GLUT-2 is the constitutive transporter 
protein of the beta cell and it is fairly 
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specifically expressed in these cells. This 
leads to the enhanced uptake of STZ and 
restriction of greatest damage to the beta 
cells (Schnedl WJ et al., 1994). STZ is 
generally used in the rat or the mouse, but 
STZ also functions in humans and has been 
used in cancer chemotherapy of e.g. malign 
insulinomas, pancreatic tumors originating 
from insulin-secreting cells (Murata E et al., 
1985). During antineoplastic treatment 
regimens involving the administration of 
STZ the patients are monitored carefully, 
since in humans STZ is known to cause 
acute renal tubular toxicity (Sadoff L, 1970; 
Kintzel PE, 2001) and progressive renal 
failure can be prevented by drug 
discontinuance (Ries F et al., 1986). Such 
acute nephrotoxicity is not seen in rats 
(Rakieten N et al., 1963; Junod A et al., 
1967; Kraynak AR et al., 1995). However, 
in experimental animals, STZ is 
carcinogenic: even a single diabetogenic 
administration induces tumors in rat kidney, 
liver and pancreas (Rakieten N et al., 1968; 
Bolzan AD et al., 2002). Although STZ is 
possibly carcinogenic in humans as well 
these effects require further study (Bolzan 
AD et al., 2002). A genotoxicologic work 
studying the extent and persistence of DNA 
damage caused by STZ in rat kidney 
reported that a commonly used diabetogenic 
dose of 60 mg/kg STZ induced extensive 
DNA damage which required up to 3 weeks 
to be repaired. The authors concluded that 
the STZ model should be avoided when the 
enhancement of tumorigenesis may be an 
unwanted complication. Further, they 
suggest that in studies testing for the effects 
of any drug a delay of 3 to 4 weeks should 
be given before the start of treatment to 
allow the greatest possible repair of DNA 
damage (Kraynak AR et al., 1995). 
The STZ model in the rat and the 
mouse is most useful in areas of research 
concerning the adverse effects of 
hyperglycemia. There is also a modification 
of this model with multiple low-dose 
injections of STZ which leads to 
insulinopenia and development of insulitis 
with immune destruction of the pancreas. 
However, in the multiple low-dose model 
diabetes will develop even in the absence of 
functional T or B cells (Barlow SC et al., 
2004). Thus, other animal models are mainly 
used in the study of the pathogenesis of 
autoimmune insulitis leading to type 1 
diabetes. 
2.4.2.2 Non-obese diabetic mouse 
Originally described in 1980, the 
non-obese diabetic (NOD) mouse is a breed 
of mice with spontaneously developing 
autoimmune insulitis at 4-5 weeks of age, 
including infiltration of T cells into islets of 
Langerhans, ultimately destroying the 
pancreatic beta cells (Makino S et al., 1980). 
The diabetic state usually presents between 
12 to 30 weeks of age. In contrast to human 
type 1 diabetes, the incidence of diabetes in 
typical colonies of NOD mice is 
approximately 90% in females but only 60% 
in the males. In addition to diabetes, NOD 
mice spontaneously develop autoimmune 
responses in a variety of tissues, including 
salivary, lacrimal, thyroid, parathyroid, 
adrenal, testis, large bowel and red blood 
cells, and they are also susceptible to the 
experimental induction of a variety of other 
autoimmune diseases, including 
experimental autoimmune thyroiditis, 
colitis-like wasting disease, 
encephalomyelitis, and manifestations of 
systemic lupus erythematosus (Aoki CA et 
al., 2005). Despite the greater gender 
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difference in incidence, the NOD mouse can 
be considered to be a close model of human 
type 1 diabetes and it is widely used in 
research of the immunological pathogenesis 
of diabetes, whilst it is applicable to the 
study of T cell behaviour in autoimmunity in 
general (Ridgway WM, 2003). 
2.4.2.3 Biobreeding rat 
The biobreeding (BB) rat is also an 
inbred model of diabetes. The BB diabetes-
prone rats develop autoimmune diabetes 
with symptoms presenting at 12 weeks after 
birth (Nakhooda AF et al., 1977). Similar 
immunological features are seen as in the 
NOD mice, but the BB diabetes-prone rats 
characteristically have a clear T cell 
lymphopenia, which is not present in the 
human type 1 diabetes or in the NOD mice. 
With reference to renal complications, the 
BB rats seem to have an interesting relative 
resistance to diabetic nephropathy. This is 
suggested to be due to increased production 
of nitric oxide or decreased accumulation of 
advanced glycation end-products (Feld LG 
et al., 1995), both of which are important 
mediators in the development of diabetic 
nephropathy as discussed in chapter 2.5. 
Nevertheless, the BB rat has been used in a 
range of studies concerning the development 
of diabetic nephropathy. 
There exists also another strain of the 
BB rat, the BB diabetes-resistant rat, which 
does not develop spontaneous diabetes. 
However, when BB diabetes-resistant rats 
are infected with the Kilham’s rat virus, they 
develop autoimmune insulitis and diabetes 
(Guberski DL et al., 1991). The Kilham’s rat 
virus -induced diabetes in the BB diabetes-
resistant rat is therefore a useful model for 
studying the role of viruses in the 
pathogenesis of autoimmune beta cell 
destruction. 
2.4.2.4 Transgenic and other animal 
models of diabetes 
Other intriguing models of diabetes 
include the Long-Evans Tokushima lean 
(LETL) rat and Komeda diabetes-prone 
(KDP) rat as well as a model with proteins 
of the lymphocytic choriomeningitis virus 
expressed under the rat insulin promoter 
(RIP-LCMV). The LETL rat is another rat 
model of type 1 diabetes. This rat strain 
develops a spontaneous disease with 
lymphocyte infiltration into pancreatic islets 
and a sudden onset of diabetic symptoms. 
The incidence of diabetes is only 
approximately 20%. No lymphopenia or sex 
difference in incidence or severity is seen 
(Kawano K et al., 1991). Subsequently, two 
substrains have been derived from the LETL 
rat: a non-diabetic strain and a diabetes-
prone strain. The latter strain is called the 
KDP rat and it has an overall 70% incidence 
of diabetes (Komeda K et al., 1998). RIP-
LCMV is an interesting model for 
autoimmune diabetes developed 
independently by two groups in 1991 
(Ohashi PS et al., 1991; Oldstone MB et al., 
1991). These mice lose the tolerance for the 
LCMV epitopes and develop diabetes after 
infection with LCMV due to an immune 
response against the viral epitopes in the 
beta cells. Various transgenic animals with 
increased or decreased number of gene 
copies of diabetes-related genes have 
recently been engineered. Also the 
possibility to develop mouse models with 
tissue-specific gene knock-outs of single 
genes has been utilized in recent diabetes 
research. See Table 2.4 for summary of 
several informative transgenic animal 
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models of diabetes. There exists also a range 
of other animals such as hamsters, rabbits, 
dogs, and apes with spontaneous 
development of autoimmune diabetes 
resulting in complications such as diabetic 
nephropathy (Kramer JW et al., 1980; 
Conaway HH et al., 1981). However, most 
of these animals are larger than the rodents 
described above and are not convenient for 
laboratory research. Furthermore, ethical 
principles favour the use of rodents in 
animal studies. 
Table 2.4: Transgenic animal models in diabetes research 
Target gene Model type Effects Reference 
Insulin 
receptor 
Mouse gene knockout Neonatal lethality Joshi RL et al., 1996 
Insulin 
receptor 
Expression of kinase deficient 
human insulin receptor in 
transgenic mice 
Decreased insulin sensitivity in vivo Chang PY et al., 1994 
Insulin 
receptor 
Mouse pancreatic beta cell –
specific gene knockout 
Insulin secretory defect similar to human 
type 2 diabetes 
Kulkarni RN et al., 1999 
Insulin 
receptor 
substrate -1 
Mouse gene knockout Insulin resistance and growth retardation Tamemoto H et al., 1994 
Insulin 
receptor 
substrate -2 
Mouse gene knockout Type 2 diabetes –like symptoms, liver 
insulin resistance and lack of 
compensatory beta cell hyperplasia 
Withers DJ et al., 1998; 
Kubota N et al., 2000 
Glucokinase Mouse gene knockout Perinatal lethality with hyperglycaemia Grupe A et al., 1995 
HLA DRB1 
and 
DQA1/DQB1 
Expression of predisposing 
human DR3 and/or DQ8 in 
transgenic mice 
Development of spontaneous insulitis Abraham RS et al., 2000 
GLUT4 
receptor 
Expression of normal human 
GLUT4 receptor in transgenic 
mice 
Efficient glycemic control Liu ML et al., 1993 
PPAR-γ Mouse pancreatic beta cell –
specific gene knockout 
Abnormalities in islet mass, normal 
glucose homeostasis 
Rosen ED et al., 2003 
2.5 Mechanisms of diabetic nephropathy 
2.5.1 Pathological changes in the function 
and structure of the glomerulus 
Under conditions of sustained 
hyperglycaemia, the glomerular cells are 
affected by various mechanisms, which will 
be discussed below. These changes lead to 
altered structure and function in the 
glomerulus. In large part, similar changes 
take place also in the retina and the 
peripheral nerve, the two other locations of 
microvascular structures subject to 
pathological changes in diabetes (Kumar V 
et al., 1992). 
In the kidney, the first observed 
functional change is an abnormally 
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increased GFR (Ditzel J et al., 1967). This 
change develops before any major 
histological change in the glomerular 
structure. Later in the development of 
diabetic nephropathy, typical histologically 
visible changes are seen: thickened GBM, 
diffuse glomerulosclerosis, nodular 
glomerulosclerosis (the pathognomonic 
Kimmelstiel-Wilson lesions), exudative 
lesions in the Bowman’s capsule and 
podocyte loss (Kumar V et al., 1992; Nishi S 
et al., 2000). Also the intraglomerular 
pressure tends to rise (Hostetter TH, 1991). 
In a clinical setting, the most important sign 
of diabetic nephropathy is proteinuria which 
often worsens during the course of disease. 
Ultimately, end-stage renal failure may 
develop. The detection of very low but yet 
increased levels of albumin in urine have 
been used in predicting the development of 
overt diabetic nephropathy (Parving HH et 
al., 1982; Viberti GC et al., 1982; Mogensen 
CE et al., 1984). However, this measurement 
of microalbuminuria has certain limitations 
due to the spontaneous regression from 
persistent microalbuminuria back to 
normoalbuminuria (Hovind P et al., 2004). 
Moreover, up to 12% of completely normal 
human individuals in all ethnic groups may 
show sporadic albuminuria, thus more 
specific markers for predicting the risk of 
diabetic nephropathy are needed (Caramori 
ML et al., 2000). 
2.5.2 Molecular biological and biochemical 
mechanisms 
The histological and functional 
changes described above are derivatives of 
alterations at the molecular level. During the 
course of diabetic nephropathy, due to high 
intra- and extracellular glucose 
concentration, advanced glycation end-
products (AGEs) are formed, various 
signalling pathways are activated and there 
is an increased flux through the polyol and 
hexosamine pathways (Brownlee M, 2001). 
See Figure 2.5 for an overview of the 
parallel pathologic processes involved in the 
development of diabetic nephropathy. Also 
increased oxidative stress due to intracellular 
hyperglycemia is suggested to influence the 
pathologic changes (Giugliano D et al., 
1996). Consequently, alterations in the 
functional integrity of a multitude of 
proteins and also in the gene expression 
patterns of growth factors, cytokines and 
other molecules are seen. Below, the 
involvement of AGEs and various growth 
factors in the pathogenesis of diabetic 
nephropathy are addressed in more detail. 
2.5.2.1 Advanced glycation end-products 
The AGEs were long considered to 
be the result of a completely non-enzymatic 
process, in which protein glycation 
randomly takes place under abnormally high 
glucose concentrations. However, it has 
been shown that the intracellular dicarbonyl 
formation is likely a prerequisite of 
significant protein glycation (Degenhardt TP 
et al., 1998). These highly reactive 
dicarbonyls are formed as a result of auto-
oxidation of glucose to glyoxal (Wells-
Knecht KJ et al., 1995), degradation of 
glyceraldehyde-3-phosphate or 
dihydroxyacetone phosphate to 
methyglyoxal (Thornalley PJ, 1990), and 
decomposition of the Amadori product to 3-
deoxyglucosone (Brownlee M, 2001). 
Reaction of dicarbonyls with amino groups 
in proteins leads to the formation of AGEs 
(Degenhardt TP et al., 1998). In further 
developed stages of AGE formation, the 
structure and function of affected proteins 
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are altered. Intracellular signalling may be 
modified by these changes. Equally, the 
function of extracellular macromolecules 
and proteins is distorted (Tanaka S et al., 
1988; Tsilibary EC et al., 1988; Charonis AS 
et al., 1990). For example, Tanaka et al. 
showed that the molecular packing of type I 
collagen is expanded due to intermolecular 
crosslinking by AGEs (Tanaka S et al., 
1988). It has now become evident that there 
is also at least one major receptor for AGEs 
mediating the adverse effects (Neeper M et 
al., 1992; Vlassara H et al., 1995). This 
receptor for AGE (RAGE) has signalling 
properties as well and it is found to be 
upregulated in human tissues susceptible to 
the complications of diabetes (Kim W et al., 
2005), hence RAGE is suggested to 
contribute to the pathogenesis of diabetes 
and its complications. AGE formation takes 
place also in the circulation and altered 
plasma proteins are bound to endothelial 
AGE receptors causing endothelial 
dysfunction (Yan SD et al., 1994; Lander 
HM et al., 1997; Smedsrod B et al., 1997). 
RAGE has also been found to be expressed 
in the podocyte and in a model of diabetic 
nephropathy, it has been shown to be 
required for the mediation of the adverse 
effects of AGE (Wendt TM et al., 2003). 
2.5.2.2 Intracellular signalling pathways 
and growth factors mediating the 
pathological changes 
Intracellular hyperglycaemia leads to 
increased de novo synthesis of 
diacylglycerol (DAG) which is a key 
intracellular metabolite and among others an 
activator of several protein kinase C (PKC) 
isoforms, most importantly the PKC-β 
isoforms (Koya D et al., 1998). Other 
pathways of PKC activation are also 
suggested, such as AGE receptor –ligation 
and increased activity of the polyol pathway 
due to activation of aldose reductase 
(Ramana KV et al., 2005). This leads to a 
great number of pathologic changes, such as 
increased production of endothelial nitric 
oxide synthase (eNOS), endothelin-1, 
vascular endothelial growth factor (VEGF), 
transforming growth factor beta (TGF-β), 
plasminogen activator inhibitor 1 (PAI-1), 
nuclear factor kappa B (NF-κB), and the 
activation of nicotinamide adenine 
dinucleotide (NADH) and nicotinamide 
adenine dinucleotide phosphate (NADPH) -
oxidases (Brownlee M, 2001). As the renin-
angiotensin system (RAS) gets activated in a 
patient with type 1 diabetes, angiotensin II 
levels increase (Ganong WF, 2003a). The 
activation of the angiotensin receptor in the 
mesangial cells is known to further stimulate 
TGF-β production and extracellular matrix 
(ECM) production (Wolf G et al., 1997). 
Since TGF-β is a secreted growth factor, it 
effects also on the podocyte in a paracrine 
manner. 
The TGF-β seems to play a central 
role as a mediator in the pathologic changes 
in the glomerulus. It has been shown that the 
AGE formation, PKC activation, angiotensin 
II, and shear stress increase TGF-β 
expression (Gnudi L et al., 2003). TGF-β is 
a potent growth factor promoting the 
deposition of ECM components, such as 
collagen I, IV and fibronectin. This leads to 
the histologically evident glomerular 
expansion and thickening of the basement 
membrane. The effects of TGF-β are 
mediated by the TGF-β receptor type II 
(Ziyadeh FN, 2004), while the Smad-
pathway is the downstream intracellular 
signalling pathway involved in TGF-β 
signalling (Wang W et al., 2005). Also the 
connective tissue growth factor (CTGF)  
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Figure 2.5: An overview of the signalling pathways involved in the pathogenesis of diabetic 
nephropathy. 
 
stimulates ECM synthesis. The increase in 
ECM synthesis induced by AGEs has 
recently been shown to be mainly mediated 
by the CTGF (Zhou G et al., 2004) in rat 
mesangial cells. TGF-β also upregulates the 
expression of GLUT-1, the cell surface 
receptor for glucose in renal cells (Inoki K et 
al., 1999). Thus, glucose influx increases 
and the intracellular glucose-induced 
metabolic abnormalities are accelerated. 
Another important mediator seems to 
be the VEGF. Hyperglycaemia increases 
VEGF excretion in the mesangial cell and 
podocyte via pathways involving PKC and 
extracellular signal-regulated kinase (ERK) 
(Kim YH et al., 2001; Hoshi S et al., 2002). 
Receptors for VEGF in the glomerulus are 
found in the endothelial cells and it is 
thought that this growth factor increases the 
permeability of the glomerular endothelium 
and is therefore responsible for the 
hyperfiltration seen in early diabetic 
nephropathy. Also mechanical stretch 
mimicking the shear stress caused by 
hyperfiltration and increased glomerular 
pressure increased the excretion of VEGF in 
the mesangial cells. In a study demonstrating 
this effect it seemed that the effects of shear 
stress in mesangial cells are mediated via a 
pathway dependent on PKC and protein 
tyrosine kinase (PTK) since the combined 
inhibition of these enzymes completely 
prevented the increased VEGF excretion in 
an in vitro experiment (Gruden G et al., 
1997). 
A fourth growth factor, the platelet 
derived growth factor beta (PDGF-β) is also 
involved in the histological alterations in the 
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glomerulus. Under high glucose 
concentrations the PDGF-β growth factor 
and the corresponding receptor are 
upregulated in the mesangial cell leading to 
later increase in TGF-β expression (Di Paolo 
S et al., 1996). 
2.5.3 Genetic risk factors for diabetic 
nephropathy 
Support for the existence of 
hereditary susceptibility to diabetic 
nephropathy emerges from epidemiologic 
observations. Studies of families of patients 
with diabetic nephropathy have shown an 
increased risk in the relatives (Seaquist ER 
et al., 1989). Also, the differences between 
various ethnic groups in development of 
diabetic nephropathy support the genetic 
aspect. Examples of this are the Pima 
Indians, who in addition to having a high 
incidence of type 2 diabetes, have an 
elevated risk for diabetic nephropathy as 
well (Pettitt DJ et al., 1990). In families of 
African American patients with type 2 
diabetes -induced end-stage renal disease the 
relatives have an eightfold risk of 
developing diabetic nephropathy, as 
compared to the relatives of a type 2 diabetic 
control population without renal 
complications (Freedman BI et al., 1995). 
Also, in a Finnish material the presence of 
type 2 diabetes in the parents of a type 1 
diabetic patient affected the risk of diabetic 
nephropathy (Fagerudd JA et al., 1999). This 
effect could be due to genetic and/or 
environmental factors passed on in the 
family. 
Efforts to identify the genetic factors 
modulating the risk for diabetic nephropathy 
have not yielded much result. However, 
some candidate genes have been identified 
and several other susceptibility loci are 
proposed to associate with diabetic 
nephropathy. Candidate genes studied 
include the ACE gene, endothelial nitric 
oxide synthase gene (NOS3), 
angiotensinogen, angiotensin II type 1 
receptor, apolipoprotein E and TGF-β 
(Merta M et al., 2003). Also single-
nucleotide polymorphisms in the promoter 
region of the PKC-β1 gene are suggested to 
associate with the development of diabetic 
nephropathy (Araki S et al., 2003). Other 
suggested functional candidates include the 
aldose reductase gene AKR1B1 and 
carnosinase genes CNDP1 and CNDP2 (Sale 
MM et al., 2006). Carnosinase has a function 
as a scavenger of reactive oxygen species, 
and thus reduces the formation of AGEs. As 
diabetic nephropathy is considered to be a 
complex disease with a polygenic 
background, candidate gene studies are often 
unsuccessful or too unreliable, whilst genetic 
linkage studies have been difficult to 
perform due to the lack of extended 
pedigrees (Lindner TH et al., 2003). With 
special reference to the podocyte proteins, a 
linkage analysis of 212 sibling pairs 
excluded the association of nephrin, 
podocin, CD2AP or the Wilms tumor loci 
with diabetic nephropathy (Iyengar SK et al., 
2003). 
2.5.4 Immunological studies on 
mechanisms of diabetic nephropathy 
2.5.4.1 Inflammation 
Recently increased levels of 
inflammatory markers such as C-reactive 
protein and interleukin-6 were found to be 
present in type 1 diabetic patients with 
micro- or macroalbuminuria (Saraheimo M 
et al., 2003). The origin of the inflammation 
remains unclear. However, this finding 
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suggests that the pathogenetic mechanisms 
of diabetic nephropathy also involve the 
immunological and inflammatory process. 
This mechanism is further supported by the 
finding that diabetic mice deficient in 
intercellular adhesion molecule 1 (ICAM-1), 
a molecule mediating macrophages to 
diabetic kidney, are protected against renal 
injury (Okada S et al., 2003). It is also 
known that the activation of PKC in the 
mesangial cell induces the expression of 
ICAM-1 (Park CW et al., 2000). This links 
the metabolic disturbances and alterations in 
intracellular signalling in diabetes to 
inflammation (Tuttle KR, 2005). 
2.5.4.2 Oxidized LDL autoantibodies 
Increased oxidative stress due to 
hyperglycaemia is suggested to be involved 
in the pathogenesis of diabetic nephropathy, 
as discussed earlier in this chapter. It is 
known that oxidized low-density lipoprotein 
(LDL) is immunogenic and forms 
immunocomplexes with corresponding 
antibodies and that these immunocomplexes 
are atherogenic and promote inflammation 
(Lopes-Virella MF et al., 1996). Therefore, 
the possible role of oxidized LDL in 
development of diabetic complications has 
been studied and several independent 
authors have reported that there seems to be 
no relation between oxidized LDL 
autoantibodies and albuminuria (Korpinen E 
et al., 1997; Leinonen JS et al., 1998; 
Willems D et al., 1998). However, in 2002 it 
was found out that a high concentration of 
these immunocomplexes formed of 
antibodies with high avidity does indeed 
relate to proteinuria in diabetic patients 
(Atchley DH et al., 2002). 
2.5.4.3 Other factors 
Studies on other autoantibodies 
present in patients with diabetes, such as 
phospholipid and GADA have shown no 
correlation between these autoantibodies and 
nephropathy in diabetes (Roll U et al., 1995; 
Vinik AI et al., 1995). Sulphatide is a 
preferentially neural epitope found also in 
the islets of Langerhans and in the kidneys 
of diabetic BB rats (Buschard K et al., 
1993). Anti-sulphatide antibodies have been 
suspected to be involved in the pathogenesis 
of diabetic complications but the available 
data do not give further support to this 
hypothesis. Recently, the immunological 
pathogenetic aspect has been supported by 
the finding that circulating immune 
complexes of IgG antibodies are associated 
with early diabetic nephropathy (Nicoloff G 
et al., 2004). Already in 1972, linear 
deposits of immunoglobulin along with 
complement in glomeruli of diabetic rats 
were detected (Mauer SM et al., 1972). This 
has been verified by another study published 
in 1981 (Axe SR et al., 1981). The exact 
pathogenic function of these 
immunoglobulin deposits in diabetic 
glomeruli is not clear, although it is evidence 
of the involvement of immunological factors 
at some stage in this complication. 
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2.6 Proteins of the podocyte foot process 
A multitude of podocyte proteins 
relevant to the filtration slit function has 
recently been discovered. The protein 
components of the foot process are listed in 
Table 2.6., and a schematic representation of 
these proteins in the podocyte foot process is 
shown in Figure 2.6.1. 
2.6.1 Apical foot process membrane 
The apical side of the podocyte foot 
process is facing the urinary space. On the 
apical membrane, podocalyxin is an 
important transmembrane protein with a 
strongly glycosylated and negatively 
charged extracellular part (Kerjaschki D et 
al., 1984). Podocalyxin molecules are 
thought to contribute to keeping the filtration 
pores open by holding up anionic repulsion 
between the opposing foot processes. 
Podocalyxin is connected to the actin 
cytoskeleton via the Na+/H+ exchanger 
regulatory factor 2 (NHERF-2) and ezrin 
(Takeda T, 2003). The importance of 
podocalyxin to the structure of the foot 
process is corroborated by the phenotype of 
podocalyxin knock-out mice, which present 
with anuria and perinatal lethality. In the 
glomeruli of these mice podocytes are 
present but lack foot processes (Doyonnas R 
et al., 2001). 
Glomerular epithelial protein-1 
(GLEPP1) is a membrane protein-tyrosine 
phosphatase (PTPase) with a large 
extracellular domain containing eight 
fibronectin type III-like repeats, a 
hydrophobic transmembrane segment, and a 
single PTPase domain (Thomas PE et al., 
1994). It is suggested that GLEPP1 regulates 
the glomerular filtration via effects on the 
podocyte structure and function, since mice 
deficient in GLEPP1 have a decreased GFR, 
a low number of podocyte foot processes 
and reduced expression of nephrin 
(Wharram BL et al., 2000). 
Megalin is a multiligand endocytic 
receptor protein of the low-density 
lipoprotein receptor-related protein (LRP) 
family found all over the podocyte cell 
membrane in murine glomeruli. Megalin 
seems to be involved in the uptake of 
lipoproteins from the extracellular space 
(Kerjaschki D et al., 1983; Kerjaschki D et 
al., 1997). It also has a wide variety of other 
ligands, such as 25-OH vitamin D (Leheste 
JR et al., 2003), and in the kidney megalin is 
mainly expressed at the epithelium of the 
proximal tubules where it is a highly active 
endocytic protein. Megalin is also present at 
the basal aspect of the podocyte foot 
process. It should be noted, however, that so 
far megalin has not been shown to be 
expressed in the human podocyte. The 
membrane-associated guanylate kinase 
inverted protein 1 (MAGI-1) has been 
shown to bind megalin (Patrie KM et al., 
2001). MAGI-1 seems to be linked to the 
cytoskeleton and it is expressed in the 
human kidney where it closely parallels the 
expression of GLEPP1. MAGI-1 interacts 
with various proteins and it is proposed to 
function as a scaffolding protein. 
The junctional adhesion molecule 4 
(JAM4) is also localized to the apical 
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membrane close to ezrin. JAM4 interacts 
with MAGI-1 and it has been suggested to 
have a different role at the apical podocyte 
foot process besides the role as a junctional 
molecule (Harita Y et al., 2005).  
2.6.2 Lateral podocyte membrane 
2.6.2.1 Nephrin and other cell adhesion-
associated molecules 
Nephrin gene NPHS1 is located in the 
human chromosome 19q13.1. Nephrin is a 
transmembrane protein with 1241 amino 
acids, and it belongs to the immunoglobulin 
superfamily of cell adhesion molecules. 
Nephrin contains one fibronectin-like 
domain, eight Ig-like domains and a short 
intracellular part. Due to the presence of 
several tyrosine residues in the intracellular 
domain, nephrin has signalling capabilities. 
The congenital nephrotic syndrome of the 
Finnish type (CNF) is caused by mutations 
in NPHS1 (Kestilä M et al., 1998). Nephrin 
was the first identified structural protein of 
the podocyte slit diaphragm (Ruotsalainen V 
et al., 1999). Nephrin mRNA is known to be 
alternatively spliced to one additional form 
in the human (Holthöfer H et al., 1999a) and 
to four additional splice variants in the rat 
(Ahola H et al., 1999). One of these, the 
variant nephrin-α, is lacking the exon 24 
encoding the transmembrane part, and could 
therefore translate into a soluble form of 
nephrin. The role of these splicing variants 
has not been conclusively established. Along 
with the expression in the kidney, nephrin 
expression has been also revealed in the 
pancreas (Palmen T et al., 2001; Zanone 
MM et al., 2005), brain (Putaala H et al., 
2001), testis (Liu L et al., 2001) and placenta 
(Beall MH et al., 2005). However, a 
contradictory report states that nephrin 
expression is restricted to kidney, and that 
CNF patients devoid of nephrin do not seem 
to suffer from major clinical symptoms 
referring to the above mentioned organs 
(Kuusniemi AM et al., 2004). As already 
described in chapter 2.5., the PKC activity is 
increased in the glomerular mesangial cells 
as well as in the podocytes. It has been 
shown that the expression of nephrin mRNA 
in the podocyte increases with the activation 
of PKC (Wang SX et al., 2001b). 
Interestingly, human podocytes seem to be 
responsive to regulation by insulin (Coward 
RJ et al., 2005b) and nephrin appears to have 
a critical role for this action (Coward RJ et 
al., 2005a). 
In addition to nephrin, a set of other 
adhesion proteins have been localized to the 
podocyte filtration slit. Neph1, -2 and -3 are 
three closely related transmembrane proteins 
of the immunoglobulin superfamily, with 5 
extracellular Ig-type domains and an 
intracellular part with signalling capabilities 
(Ihalmo P et al., 2003; Sellin L et al., 2003). 
To avoid misunderstandings, it should be 
noted that Neph3 is also known as filtrin or 
KIRREL-2. The Neph-proteins have 
substantial homology to nephrin and they are 
all shown to interact with podocin. The 
extracellular parts of Neph1 (Barletta GM et 
al., 2003) and Neph2 (Gerke P et al., 2005) 
interact with nephrin as well. Similarly to 
nephrin, Neph1 is crucially important to the 
structure and function of the podocyte 
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Table 2.6: Principal protein components at the membranes of podocyte foot process 
Membrane 
area 
Protein Description Reference 
Apical Podocalyxin Transmembrane protein keeping the filtration pores 
open 
Kerjaschki D et al., 1984 
 NHERF-2 Intracellular protein linking podocalyxin to the 
cytoskeleton 
Takeda T, 2003 
 Ezrin Intracellular protein linking podocalyxin to the 
cytoskeleton 
Takeda T, 2003 
 GLEPP1 Transmembrane protein possibly regulating glomerular 
filtration 
Thomas PE et al., 1994 
 Megalin Multi-ligand transmembrane receptor molecule Kerjaschki D et al., 1983 
 MAGI-1 Intracellular cytoskeleton-linked protein interacting 
with megalin and JAM4 
Patrie KM et al., 2001 
 JAM4 Transmembrane junctional molecule with unknown 
function at the apical membrane 
Harita Y et al., 2005 
 TRPC6 Cation-channel at cell surface important for renal 
function 
Reiser J et al., 2005 
Lateral Nephrin Transmembrane cell adhesion molecule important for 
the slit diaphragm 
Ruotsalainen V et al., 
1999 
 Neph1/2/3 Three closely related transmembrane proteins 
contributing to the slit diaphragm 
Ihalmo P et al., 2003; 
Sellin L et al., 2003 
 Densin Transmembrane adhesion molecule suggested to 
maintain podocyte cell membrane polarity 
Ahola H et al., 2003 
 P-cadherin Transmembrane adhesion molecule located to the slit 
diaphragm 
Reiser J et al., 2000 
 Catenins Intracellular binding partners of P-cadherin, linking it 
intracellularly to ZO-1 and FAT 
Reiser J et al., 2000 
 FAT Transmembrane molecule contributing to the slit 
diaphragm 
Inoue T et al., 2001 
 MEGF1 Transmembrane molecule contributing to the slit 
diaphragm 
Sun Y et al., 2005 
 VASP Intracellular protein binding to FAT1 and actin 
cytoskeleton 
Moeller MJ et al., 2004 
 Podocin Integral transmembrane protein interacting with 
nephrin, Neph-proteins and CD2AP 
Roselli S et al., 2002 
 CD2AP Cytoplasmic protein interacting with nephrin and 
podocin to facilitate signalling 
Shih NY et al., 2001 
 ZO-1 Large cytoplasmic protein binding Neph-proteins Kawachi H et al., 1997 
Basal Dystroglycans Anchors the podocyte to the basement membrane Raats CJ et al., 2000 
 Utrophin Connects the dystroglycan complex to the cytoskeleton Raats CJ et al., 2000 
 α3β1-integrin Anchors the podocyte to the basement membrane Regoli M et al., 1997 
 Podoplanin Transmembrane protein maintaining foot process in 
shape 
Matsui K et al., 1998 
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Figure 2.6.1. A schematic representation of the proteins of the podocyte foot process. 
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filtration slit as mice deficient in Neph1 
suffer from proteinuria and perinatal 
lethality (Donoviel DB et al., 2001). 
Densin is a transmembrane protein 
belonging to the leucine-rich repeats and 
PDZ -family of proteins (LAP) with a 
domain configuration similar to several 
adhesion molecules (Apperson ML et al., 
1996). It is localized in the brain in neuronal 
dendrites at synapses where it is known to 
have interactions with alpha-actinin-4 
(Walikonis RS et al., 2001). LAP proteins 
are suggested to maintain cell polarity 
(Bilder D et al., 2000). In the podocytes 
densin has been shown to be expressed at the 
slit diaphragm, and based on the role of 
densin in the neuronal cells it is proposed 
that it maintains podocyte apical-basal 
polarity (Ahola H et al., 2003). 
The adhesion molecule P-cadherin 
and proteins alpha-, beta- and gamma-
catenin have been found in cultured 
podocytes (Reiser J et al., 2000) and at the 
slit diaphragm (Xu ZG et al., 2005). They 
are all associated with the adherens-type cell 
junction. However, there is also one 
incongruous report of P-cadherin and alpha- 
and beta-catenin expression in the rat, where 
immunostaining in the podocyte was seen 
only in the developing kidney (Yaoita E et 
al., 2002). The expression of P-cadherin is 
known to decrease in STZ rats already at 6 
weeks, suggesting its involvement in the 
pathological changes of early diabetic 
nephropathy (Xu ZG et al., 2005). 
FAT is a novel member of the 
cadherin family, and it is shown to be a 
component of the slit diaphragm (Inoue T et 
al., 2001; Yaoita E et al., 2002). FAT is a 
large molecule of approximately 4600 amino 
acid residues that has a long extracellular 
domain. According to recent publications it 
is evident that another large protein of the 
same family, known as the protein 1 with 
multiple EGF-like domains (MEGF1/Fat2), 
is present at the slit diaphragm as well (Sun 
Y et al., 2005). The intracellular part of FAT 
is shown to bind to vasodilator-stimulated 
phosphoprotein (VASP) and is necessary for 
cell polarization and actin cytoskeleton 
assembly (Moeller MJ et al., 2004). VASP 
takes part in the actin cytoskeleton 
organization together with palladin, an actin-
binding cytoplasmic protein (Boukhelifa M 
et al., 2004). Palladin is a protein associated 
to actin filament assembly and it may 
interact with ezrin (Mykkanen OM et al., 
2001). 
2.6.2.2 Scaffold proteins and signal 
transducers at the slit diaphragm 
The intracellularly important binding 
partners of nephrin seem to be podocin and 
CD2AP. Podocin is located at the podocyte 
filtration slit area (Roselli S et al., 2002) and 
it belongs to the stomatin family of proteins. 
Stomatins are integral transmembrane 
proteins with intracellular amino- and 
carboxytermini (Schwarz K et al., 2001). 
The gene encoding podocin, NPHS2, is 
mutated in familial and sporadic focal 
segmental glomerulosclerosis (Boute N et 
al., 2000; Karle SM et al., 2002) and in some 
patients with a phenotypic CNF without 
mutations in nephrin (Koziell A et al., 2002). 
As mentioned above, podocin interacts with 
the Neph-proteins, nephrin and CD2AP, and 
it is suggested that it provides a scaffold for 
the nephrin-associated protein complex in 
the podocyte slit diaphragm. Similar to other 
stomatins, podocin is associated with lipid 
rafts (Schwarz K et al., 2001) and recruits 
nephrin and Neph-proteins to these lipid 
rafts to facilitate nephrin signalling (Huber 
TB et al., 2001; Huber TB et al., 2005). The 
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member 6 of the transient receptor potential 
cation channel subfamily C (TRPC6) is a 
cation-channel localized to podocyte cell 
membranes (Reiser J et al., 2005). Mutation 
in the channel is another causative factor for 
familial focal segmental glomerulosclerosis 
(Winn MP et al., 2005). The possible linking 
mechanism for TRPC6 and podocin to cause 
focal segmental glomerulosclerosis is not 
known. However, recent work suggests that 
the regulation of the TRPC6 might be 
associated with normal nephrin function in 
the podocyte (Trouet D et al., 2005). CD2AP 
is an 80 kilodalton (kDa) cytoplasmic 
protein connected to the intracellular C-
terminal domain of nephrin via its C-
terminal domain (Shih NY et al., 1999; Shih 
NY et al., 2001). CD2AP has been widely 
studied in association to T-cell contacts, 
where it is important for the cytoskeletal 
polarity and receptor patterning (Dustin ML 
et al., 1998). It is important to the signalling 
function of nephrin as well. 
Nephrin-associated signalling is 
depicted in Figure 2.6.2. Nephrin is 
associated with lipid rafts which are 
signalling-associated microdomains on the 
cell membrane. When these lipid rafts were 
disrupted by antibodies against a podocyte-
specific lipid raft component, the foot 
processes effaced and nephrin was 
phosphorylated and dislocated to the apical 
area of the foot process membrane (Simons 
M et al., 2001). Similarly nephrin antibodies 
disrupt the cell-cell connections 
(Khoshnoodi J et al., 2003) and cluster 
nephrin, which leads to phosphorylation of 
nephrin by Src kinases (Lahdenpera J et al., 
2003). In particular, the Src kinase family 
member Fyn has been shown to 
phosphorylate the cytoplasmic end of 
nephrin and intensify the binding of nephrin 
with podocin (Li H et al., 2004). 
Furthermore, the action of Fyn kinase on 
nephrin enables the binding of 
phosphoinositide 3-OH kinase (PI3K) to the 
intracellular nephrin-podocin-CD2AP 
complex (Huber TB et al., 2003a). PI3K is a 
heterodimer comprising a regulatory subunit 
p85 and a catalytic subunit p110. The p85 
recognizes the phosphorylated nephrin and 
allows the p110 to phosphorylate 
phospholipids at the inner leaflet of the lipid 
bilayer stimulating the serine-threonine 
kinase AKT. Further downstream 
phosphorylation occurs, and one 
phosphorylated protein is Bad, a 
proapoptotic factor. Phosphorylation of Bad 
protects the podocyte from apoptosis 
induced by detachment (Huber TB et al., 
2003a), see also Figure 2.6.2. 
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Figure 2.6.2. Nephrin-associated signalling as suggested by Li (Li H et al., 2004) and Huber 
(Huber TB et al., 2003a). See text for details.
Other intracellular interaction 
partners for nephrin include MAGI-1, which 
is also found to bind with the 
carboxyterminal end of nephrin and is 
localized to the slit diaphragm (Hirabayashi 
S et al., 2005). Also, the scaffolding proteins 
MAGI-2, IQ motif-containing GTPase-
activating protein 1 (IQGAP1), 
calcium/calmodulin-dependent serine 
protein kinase (CASK), alpha-actinin 4, 
alpha-II-spectrin and beta-II-spectrin have 
been found to directly or indirectly associate 
with nephrin (Lehtonen S et al., 2004; 
Lehtonen S et al., 2005). These are probably 
linking the cell membrane proteins to the 
actin cytoskeleton and facilitating further 
signalling. Yet another scaffolding protein of 
the slit diaphragm is the zonula occludens 1 
(ZO-1), which is a high molecular mass 
phosphoprotein of 225 kDa located on the 
cytoplasmic aspect of the slit area (Schnabel 
E et al., 1990). ZO-1 is a known protein 
component of the tight junctions, although in 
the podocyte it apparently does not lead to 
tight junction assembly. The carboxyl 
terminus of the Neph-proteins bind to ZO-1 
(Huber TB et al., 2003b). 
2.6.3 Basal podocyte membrane 
The basal aspect of the podocyte is 
attached to the underlying basement 
membrane by multiple proteins forming 
contacts to the components of the GBM, 
such as laminin, agrin, biglycan, syndecan-4 
and glypican-1 (Pyke C et al., 1997). Alpha- 
and beta-dystroglycans are present in normal 
renal tissue (Regele HM et al., 2000) and 
link the podocyte cytoskeleton to the GBM 
extracellularly via agrin and laminin and 
intracellularly via utrophin (Raats CJ et al., 
2000). In contrast to dystroglycan complexes 
found in the skeletal and smooth muscle 
cells the epithelial dystroglycan complex in 
the podocytes does not associate with any of 
the known sarcoglycans or sarcospan 
(Durbeej M et al., 1999). The heterodimeric 
adhesion molecule α3β1-integrin localizes to 
the basal podocyte cell membrane and its 
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expression is decreased early in a model of 
diabetic nephropathy (Regoli M et al., 
1997). The α3β1-integrin anchors the 
podocyte to the GBM components laminin 
and agrin (Kerjaschki D, 2001). 
Intracellularly, α3β1-integrin is linked to the 
actin cytoskeleton via talin, vinculin and 
paxillin (Drenckhahn D et al., 1988) and in 
addition directly by binding of alpha-actinin 
to the cytoplasmic domain of β1-integrin 
(Otey CA et al., 1993). Podoplanin is a 166-
amino-acid transmembrane protein that 
apparently has a function in upholding the 
foot process structure and function 
(Breiteneder-Geleff S et al., 1997; Matsui K 
et al., 1998). Megalin, as already described 
above, is present at the basal podocyte 
membrane as well. 
 40 
3 AIMS OF THE STUDY 
This thesis aimed at the following: 
(i) To study the changes in nephrin mRNA expression in experimental nephrosis. 
(ii) To study the expression of nephrin in the early stages of diabetic nephropathy. 
(iii) To specify the nephrin expression levels in later diabetic nephropathy. 
(iv) To test whether anti-proteinuric therapies could affect the nephrin expression and other 
pathological changes in experimental diabetic nephropathy. 
(v) To find out if nephrin could act as an autoantigen in patients with type 1 diabetes, and 
(vi) whether such autoantibodies have an effect on the pathogenesis of diabetic nephropathy. 
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4 MATERIALS AND METHODS 
4.1 Human study subjects and experimental animal models 
4.1.1 Animal models 
The animal models used in this work 
were the PAN rat (I), NOD mice (II) and 
STZ rat (II and III). The experimental design 
of each study is summarized in Table 4.1. 
The details of model induction, monitoring, 
experimental preparations and sample 
collection are described in the respective 
articles. It should be noted here that due to 
previous erroneous information, the time 
points for the STZ rat sacrifices in study II 
were indeed “4”, “8”, and “12” weeks, 
instead of the “4”, “6 and 8”, and “16” 
weeks indicated in the figures of the original 
report. Likewise, the NOD mice sacrifice 
time points were “3”, “6”, and “10” weeks 
after onset of diabetes, not after birth as 
stated in study II. Corrected time point 
designations are used throughout this thesis 
and an erratum has been sent to Laboratory 
Investigation. 
Table 4.1: Experimental animal models 
Study Model type Groups by time at sacrifice n Samples collected for analysis 
I PAN rat PAN 3 days 
PAN 10 days 
control rats 10 days 
6 
6 
6 
(i) kidney tissue 
(ii) urine 
NOD mice NOD 3 weeks diabetic 
NOD 6 weeks diabetic 
NOD 10 weeks diabetic 
control micea 
3 
3 
3 
3 
(i) kidney tissue II 
STZ rat STZ 4 weeks 
STZ 8 weeks 
STZ 12 weeks 
control rats 14 weeks 
2 
4 
5 
3 
(i) kidney tissue 
(ii) urine 
(iii) blood 
III STZ rat STZ 1 week 
control 1 week 
STZ 24 weeks 
STZ + perindopril 24 weeks 
STZ + aminoguanidine 24 weeks 
control 24 weeks 
7 
7 
8 
8 
8 
8 
(i) kidney tissue 
(ii) urine 
(iii) blood 
aThe age of control mice at the time of sacrifice is not available. 
 
 42 
4.1.2 Patients with type 1 diabetes 
The patient cohort of study IV 
comprised 66 children and adolescents (43 
male, 23 female) diagnosed with type 1 
diabetes at the Department of Pediatrics, 
University of Oulu, Finland in a consecutive 
series between 1983 and 1986. The mean 
age at diagnosis was 8.2 years (range 0.9 to 
15.6 years). Serum samples from the patients 
were taken at diagnosis and 2, 5 and 10 
years later. All samples were stored at –20 
°C until analyzed. Detailed clinical data 
were available including clinical history, 
total glycated hemoglobin, HLA-DR antigen 
serotypes and levels of four diabetes-
associated autoantibodies, islet cell 
antibodies (ICA), insulin autoantibodies 
(IAA) or antibodies (IA; antibodies to 
exogenous insulin), GADA and IA-2A, in 
the same samples from which nephrin 
autoantibodies were quantified. 
Microalbuminuria was defined as albumin 
excretion ranging from 30 to 300 mg/24h 
and proteinuria as a rate exceeding 300 
mg/24h. At the time of this study, 10 
patients had been lost to follow-up. Of these, 
nine patients had moved to another region 
and one had died with a diagnosis of 
multiple sclerosis. The mean duration of 
diabetes when lost to follow-up was 8.7 
years (range 4 to 13 years). The study was 
approved by the ethics committee of the 
University of Oulu. The participants and/or 
their parents gave appropriate written 
informed consent. 
4.1.3 Control subjects 
The control group of study IV 
comprised 96 non-diabetic, unselected 
healthy subjects (48 male, 48 female) with a 
mean age of 11.3 years (range 0.5 to 18.2 
years). These control samples, gathered 
between 1989 and 1994 from children 
participating in a control study program or a 
separate school child study, were used to set 
the cut-off limit for our assay. An 
appropriate written informed consent was 
obtained. 
 
4.2 Molecular biological methods 
4.2.1 RNA isolation and complementary 
DNA synthesis 
In studies I and II, total cortical 
ribonucleic acid (RNA) was extracted from 
the frozen pieces of kidney tissue (50–150 
mg) with a single-step acid guanidium 
thiocyanate-phenol-chloroform procedure 
using Trizol reagent (Invitrogen) according 
to the manufacturer’s instructions. The 
isolated RNA was then incubated with 
RNase free DNase I (Promega) for 30 
minutes in 37° C together with human 
placental RNase inhibitor (Promega) to 
remove traces of genomic DNA. 
Complementary DNA (cDNA) was 
synthesized with Moloney Murine Leukemia 
Virus reverse transcriptase (M-MLV RT; 
Promega) from 10 µg of DNase-treated total 
RNA in the presence of oligo dT15-primer 
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(Boehringer Mannheim) and an RNase 
inhibitor as previously described (Holthöfer 
H et al., 1999b). 
In study III, the frozen glomeruli 
extracted from the sacrificed animals and 
stored at -80°C were homogenized and total 
RNA was isolated by the acid guanidinium 
thiocyanate-phenol-chloroform extraction 
method (Chomczynski P et al., 1987). The 
purified RNA was dissolved in sterile water, 
quantified spectrophotometrically and its 
concentration adjusted to 1 µg/µl. Four 
micrograms of total RNA in 10 µl of water 
was mixed with 1 µl (0.05 µg) random 
hexamers (Life Technologies) and incubated 
for 10 min at 70°C. After cooling on ice for 
2 min, 2 µl of 10x polymerase chain reaction 
(PCR) buffer, 2 µl of 25 mmol/l MgCl2, 1 µl 
of 10 mmol/l deoxyribonucleotide 
triphosphate (dNTP) mix, and 2 µl of 0.1 
mol/l dithiothreitol (DTT) were added 
sequentially. Tubes were incubated at 25°C 
for 5 min, after which 1 µl of SuperScript II 
reverse transcriptase was added (200U; Life 
Technologies) and incubated at 25°C for 10 
min and at 42°C for 50 min. Reactions were 
terminated at 70°C for 15 min before chilling 
on ice. One microlitre of RNase H was 
added to each sample at incubated at 37°C 
after which samples were stored at -40°C for 
future use. Parallel reactions for each RNA 
sample were run in the absence of 
SuperScript II (genomic controls) to assess 
the degree of any contaminating genomic 
DNA. 
4.2.2 Semiquantitative RT-PCR 
In study I, semiquantitative reverse 
transcriptase PCR (RT-PCR) was used and 
the results were compared with additional 
results obtained by real-time quantitative 
TaqMan PCR, as described in the next 
paragraph. For the detection of different 
nephrin splicing forms the RT-PCR method 
instead of a less sensitive Northern blotting 
technique was used (Holthöfer H et al., 
1999b). The amounts of cDNA were 
equalized according to ß-actin levels. 
Sequence-specific oligonucleotide primers 
were designed according to the rat nephrin 
sequence. The primers used only anneal to 
the alpha splicing variant (primers RN-S3 
with RN-alpha; see Table 5.1 for primer 
sequences) corresponding to 480 
nucleotides. PCR amplifications were 
performed (total volume 25 µL) in the 
presence of 0.5µM each of the specific 
oligonucleotide primers, 0.2mM dNTP 
(Finnzymes), 10x PCR buffer with 15mM 
MgCl2 (Perkin-Elmer) and 1U AmpliTaq 
polymerase (Perkin-Elmer). PCR was run 28 
cycles for ß-actin primers or 32 cycles for 
nephrin primers (in the first cycle 
denaturation was 3 min at 94°C and 
thereafter 45 s, annealing at 56°C for 1 min 
and extension at 72°C for 45 s). PCR 
products were electrophoresed in 6% 
polyacrylamide gel and quantified with the 
National Institutes of Health Image® 
program as described previously (Holthöfer 
H et al., 1999b). 
4.2.3 Real-time quantitative PCR 
To quantitate nephrin expression 
levels in studies I, II and III, we used the 
real-time fluorescence based PCR detection 
method (TaqMan technology; PE 
Biosystems) (Laurendeau I et al., 1999). The 
TaqMan method is based on the use of a 
fluorescent-labeled probe designed for the 
sequence between the PCR primers and the 
exonuclease activity of Taq polymerase. The 
probe is labeled with a reporter dye (FAM or 
VIC; PE Biosystems) at its 5' end and a 
 44 
quencher dye (TAMRA; PE Biosystems) at 
its 3' end. When the probe is hybridized to a 
target sequence it is intact and the reporter 
dye remains quenched. In each cycle of 
amplification, the Taq polymerase releases 
increasing amounts of reporter dye 
proportional to the number of target 
sequences. The fluorescence is then 
measured with specifically designed 
instrumentation. The probe used in studies I, 
II and III was a FAM-TAMRA-labeled 
probe which was designed so that it anneals 
between nephrin-specific primers for the 
amplification of rat or mouse nephrin. See 
Table 5.1 for primer and probe sequences. 
Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) served as an endogenous control 
in studies I and II. The GAPDH mRNA 
expression values for diabetic mice and rats 
were used to normalize the amounts of 
nephrin mRNA. In study III, a commercial, 
pre-developed control kit probe designed for 
the 18S ribosomal RNA and labelled with 
the fluorescent reporter dye (VIC) on the 5' 
end and the quencher (TAMRA) on the 3' 
end was used to normalize the PCR results 
to a housekeeping gene (PE Biosystems). 
The real-time quantitative RT-PCR was 
performed using appropriate instrumentation 
according to the manufacturer's instructions 
(PE Biosystems). The derived normalized 
values are the averages of at least three runs. 
Table 5.1: Oligonucleotide primers and probes used 
Primer/probe 
name 
Description Sequence Used in 
study 
RN-S3 (forward) Rat nephrin primer 5’-agcctcttgaccatcgctaa-3’ I 
RN-alpha (reverse) Rat nephrin primer 5’-gtcctcgccttcagcacctg-3’ I 
2636U (forward) Mouse nephrin primer 5’-atctccaagaccccaggtacaca-3’ II 
2817L (reverse) Mouse nephrin primer 5’-agggtcagggcggctgat-3’ II 
2709U (forward) Rat nephrin primer 5’-taatgtgtctgcggcccag-3’ I,II,III 
2783L (reverse) Rat nephrin primer 5’-ttggtgtggtcagagccaag-3’ I,II,III 
2735U (forward) Murine nephrin probe 5’-FAM-ccctcttcaaatgcacggccacca-TAMRA-3’ I,II,III 
2316 (forward) Human nephrin primer 5’-tcgaagcttgccgccaccatggtcaactgggagagactg-3’ IV 
3723 (reverse) Human nephrin primer 5’-tacgtagaattcttacaccagatgtcccctcagctcgaa-3’ IV 
4.2.4 In situ hybridization 
For the direct detection of nephrin 
mRNA in study III, an anti-sense riboprobe 
was generated as previously described 
(Gilbert RE et al., 2000). In brief, a 293 base 
pair cDNA coding for rat nephrin was cloned 
into pGEM-T (Promega), linearized with 
Not I and an anti-sense riboprobe was 
produced using T7 RNA polymerase. The 
purified riboprobe length was adjusted to 
approximately 150 bases by alkaline 
hydrolysis. Four-µm-thick sections of rat 
kidney obtained from the experimental 
procedures in study III were cut fixed on 
slides precoated with 3-
aminopropyltriethoxysilane and baked 
overnight at 37°C. Tissue sections were 
dewaxed and rehydrated, and in situ 
hybridization was performed using 
radiolabelled riboprobe as previously 
described (Gilbert RE et al., 2000). 
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Following hybridization, slides were 
washed, dehydrated in graded ethanol, air 
dried, and exposed to Kodak X-Omat 
autoradiographic film for 3 days. Slides 
were then dipped in Ilford K5 nuclear 
emulsion, stored in a light-free box with 
desiccant at 4°C for 21 days, immersed in 
Kodak D19 developer, fixed in Ilford 
Hypan, and stained with haematoxylin and 
eosin. 
 
4.3 Immunological analysis 
 
4.3.1 Immunoblotting 
For the immunoblots in studies I and 
II, urine samples were loaded onto 8% 
sodium dodecyl sulphate polyacrylamide 
gels with reducing loading buffer. Proteins 
were electrophoresed with reducing 
conditions and electrotransferred to a 
nitrocellulose membrane as described 
previously (Reivinen J et al., 1994). To 
prevent nonspecific binding, the membrane 
was blocked by incubation in 3% bovine 
serum albumin. Primary polyclonal rabbit 
anti-nephrin antibody directed at the 
extracellular part of nephrin (Ahola H et al., 
1999), used at 1:300 (diluted in phosphate 
buffered saline with 0.1% of the soluent 
Tween-20; PBS/0.1% Tween-20), was 
applied for 60 minutes at room temperature. 
After several rinses with PBS/0.1% Tween-
20, a secondary antibody (Horseradish 
peroxidase-conjugated swine anti-rabbit 
immunoglobulins; Dako) was used at 1:2000 
and imaging with an enzymatic 
chemiluminescence (ECL) substrate was 
done with appropriate instrumentation. 
4.3.2 Immunohistochemistry 
For the immunohistochemical stains 
in study II, sagittally cut kidneys were fixed 
in 4% paraformaldehyde (in PBS) and 
embedded in paraffin. For stainings, 3 µm 
kidney sections were cut and deparaffinized, 
rehydrated, microwave-antigen unmasked, 
and incubated with 3% hydrogen peroxide 
methanol to block endogenous peroxidase 
activity. After several washes in PBS, the 
sections were blocked with 10% nonimmune 
goat serum. The primary polyclonal 
antibodies used were against the 
extracellular part of nephrin (dilution 1:50 
and incubation 60 minutes). After a 
thorough rinsing with PBS/0.05% Tween-20 
the sections were incubated for 10 minutes 
in biotinylated secondary antibody against 
rabbit immunoglobulins. The sections were 
then incubated in streptavidin-peroxidase 
after mixing with substrate-chromogen. 
Slides were counterstained with hematoxylin 
and mounted. All stages were performed 
according to instructions for peroxidase 
staining with a Histostain-DS kit (Zymed 
Laboratories). 
In study IV, normal rat kidney tissue 
was obtained from our previous experiments 
(Luimula P et al., 2002). Animals were 
treated according to the rules and regulations 
of the Ethical Committee of the University 
of Helsinki. Rat kidney tissue instead of 
human kidney tissue was chosen to avoid 
unspecific staining possibly given by human 
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serum samples. The 6 µm thick rat cortex 
cryostat sections were air-dried, fixed in 4% 
parafolmaldehyde in PBS and then blocked 
with CAS-Block (Zymed Laboratories). The 
sections were incubated with positive 
control antibody, patient serum or control 
serum diluted 1:20, 1:50 or 1:100 in 
ChemMate Antiboby Diluent (Dako) over 
night at 6°C. We used a polyclonal protein-
A-purified rabbit antibody for intracellular 
rat nephrin as the positive control (Luimula 
P et al., 2000). After three washes in PBS 
the sections were incubated with fluorescein 
isothiocyanate (FITC)-conjugated rabbit 
anti-human IgG (1:100; Dako) or 
tetramethylrhodamine isothiocyanate 
(TRITC)-conjugated goat anti-rabbit IgG 
(1:100; Jackson ImmunoResearch 
Laboratories) for 1 hour at room 
temperature. After washing the slides were 
covered with Vectashield Hard Set mounting 
medium (Vector Laboratories). Fluorescence 
microscopy was performed with an Olympus 
BX50 microscope equipped with a cooled 
digital camera (Hamamatsu Photonics). 
Corel Photo-Paint 12.0 and CorelDraw 12.0 
(Corel Corporation) software was used for 
image documentation. 
4.4 Radioimmunoprecipitation assay for detecting nephrin autoantibodies 
4.4.1 Labelled recombinant nephrin 
For the preparation of the 
radioimmunoprecipitation assay in study IV, 
normal human kidney cDNA was obtained 
from our previous experiments, as described 
elsewhere (Holthöfer H et al., 1999a). PCR 
amplification with human nephrin specific 
primers (see Table 5.1 for detailed 
sequences) was used to produce the nephrin-
specific insert, which was cloned under a T7 
promoter sequence in the circular plasmid 
vector pGEM-4z (Promega). The 
recombinant nephrin had 470 amino acid 
residues spanning from the extracellular side 
(772 methionine; GenBank accession code 
AF035835) to the intracellular C-terminal 
end (1241 valine). 35S-methionine labeled 
recombinant protein was produced by in 
vitro transcription – translation using the 
TnT T7 Coupled Reticulosyte Lysate 
System (Promega) and Redivue L-[35S] 
methionine (Amersham Biosciences) 
according to manufacturers’ instructions. 
Unincorporated 35S-methionine was 
removed by gel chromatography through a 
NAP-5 column (Amersham Biosciences). 
4.4.2 Radioimmunoprecipitation assay 
The radioimmunoprecipitation assay 
used in study IV was performed essentially 
as described earlier (Savola K et al., 1998). 
In 96-well sample plates (Wallac), 2 µl of 
patient serum and 15 000 counts per minute 
(cpm) of labeled nephrin were incubated for 
7 to 15 hours in a buffer containing 50 mM 
Tris, 150 mM NaCl and 0.1 percent Tween-
20 (TBST; pH 7.4). Then Protein A-
sepharose 4B (Zymed Laboratories) was 
added and incubation was continued for 1 to 
2 hours. After this, the samples were washed 
eight times with 140 µl of TBST, 
scintillation cocktail (OptiPhase ‘HiSafe’ 3; 
Wallac) was added and the activity 
measured. Each sample was measured in 
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duplicate and the final values are averages of 
at least two measurements. A dilution series 
(1:25, 1:50, 1:100, 1:200, 1:400) of a 
polyclonal nephrin antibody (Ahola H et al., 
1999) was used for standardization. These 
dilutions were given a relative value of 1, 
0.5, 0.25, 0.125 and 0.0625, respectively. 
The actual test samples were given a value 
in relative units (RU) using the standard 
curve of the dilution series to diminish the 
effect of interassay variation on the overall 
levels of measured activity. The intra- and 
interassay coefficients of variation were 
4.7% and 17.2%, respectively. In our assays, 
the mean level of bound nephrin label in the 
96 healthy controls was 0.066 RU with a 
standard deviation (SD) of 0.015. The cut-
off limit used was 0.10 RU and was defined 
as the 99th percentile of the values in the 
control group (mean + 2.09 SD). We 
selected this cut-off limit because of the 
background cpm in the normal control sera. 
Such background was also found in a similar 
radioligand binding assay for the detection 
of GADA (Grubin CE et al., 1994). 
To verify the specificity of our assay, 
we produced non-radiolabeled recombinant 
nephrin and performed blocking reactions. 
Briefly, to the normal assay reaction 
containing 15000 cpm labeled nephrin, we 
added an amount of non-labeled 
recombinant nephrin equivalent to 20000, 
40000 or 60000 cpm of labeled recombinant 
nephrin. Samples of nephrin autoantibody-
positive and negative diabetic patients were 
tested. As a positive control we included a 
sample of the polyclonal nephrin antibody at 
1:50 dilution. Except for the negative patient 
samples, the blocking reactions resulted in 
uniform and dose-dependent decrease of the 
measured mean cpm levels to approximately 
30%, 14% and 0%, as compared to the 
respective unblocked reaction and 
standardized to the background cpm levels 
of negative patient samples or TBST 
controls. Addition of irrelevant luciferase 
control protein to the reactions did not affect 
the results. 
 
4.5 Statistical analysis 
In studies I and II comparing the results 
of the nephrin mRNA expression 
measurements the normalized values of 
nephrin mRNA are averages of three to four 
runs and are shown as the mean ± standard 
error of the mean (SEM). The significance 
was tested using the Student’s t test and the 
Mann-Whitney U test where appropriate. 
In study III, because of its highly 
skewed distribution albumin excretion rate 
(AER) was logarithmically transformed 
before statistical analysis and expressed as 
the geometric mean x/÷ tolerance factor. 
Between group differences were analysed by 
the analysis of variance test (ANOVA) with 
correction for multiple comparisons using 
the Fisher's least significant difference test. 
Linear regression analysis was used to 
determine the correlation between the 
magnitude of nephrin gene expression and 
proteinuria. Analyses in study III were 
performed using the Statview SE+ Graphics 
package (Abacus Concepts). 
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When analysing the radiommunoassay 
results in study IV, the statistical analysis 
software (SPSS 12.0.1 for Windows; SPSS 
Inc.) was used. Normally distributed scale 
variables were compared with the use of the 
two-tailed independent samples t test. The 
nonparametric Mann-Whitney U test was 
applied to compare skewed variables. 
Categorical variables were tested with chi-
square statistics. A Kaplan-Meier survival 
curve was constructed for the time of 
diagnosis of diabetes to the time of diagnosis 
of microalbuminuria or proteinuria. By 
applying multivariate tests in a general linear 
model we analyzed the correlation of 
consecutive nephrin autoantibody titers 
within-subjects across the follow-up time 
and also compared the titer profiles between 
groups categorized by the appearance of 
microalbuminuria during the follow-up 
period. 
All given P values are two-sided and P 
values <0.05 were considered significant. 
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5 RESULTS 
5.1 Changes in nephrin expression 
5.1.1 Nephrosis model 
In the PAN model, the expression of 
nephrin-alpha mRNA decreased to 40% 
already by day 3 after induction, and at 10 
days after puromycin aminonucleoside 
treatment the expression was only 30% of 
the expression level of controls. The 
expression of full length nephrin mRNA 
decreased with close similarity (Study I, 
Figure 3). To verify the adequate precision 
of the semiquantitation method we 
performed an additional assay of the full 
length nephrin mRNA levels by TaqMan 
RT-PCR analysis. The values correlated well 
with those of the semiquantitation (Study I, 
Table 1). 
5.1.2 Diabetic nephropathy models 
5.1.2.1 Expression at the mRNA level 
In study II, the nephrin mRNA levels 
of diabetic rats had increased approximately 
50% already during 4 to 8 weeks after the 
STZ induction as compared with the control 
rats (P<0.05). At 12 weeks, in the SZT rats, 
the elevation in nephrin mRNA expression 
was not statistically significant as compared 
to the expression levels of the controls. The 
results of nephrin mRNA level 
quantifications from the STZ rats in studies 
II and III are compiled in Figure 5.1. A 
similar, statistically significant elevation of 
nephrin-specific mRNA level was seen in 
the NOD mice at 3 and 6 weeks after the 
onset of diabetes (Study II, Figure 6). At 10 
weeks in NOD mice, the nephrin mRNA 
expression level was still elevated, although 
not significantly as compared to the control 
mice. 
As studied in the 1 week diabetic 
STZ rats (study III), short-term diabetes did 
not alter nephrin gene expression. However, 
in long-term diabetic STZ rats at 24 weeks 
after model induction, nephrin mRNA 
expression was reduced to 50% compared to 
control animals. In perindopril-treated 
diabetic rats the nephrin gene expression 
was similar to control animals. In contrast, 
in the aminoguanidine-treated rats, nephrin 
expression was similar to untreated diabetic 
rats (Figure 5.1). The in-situ hybridization 
localized nephrin mRNA exclusively in the 
glomerulus. Nephrin mRNA was detected in 
a predominantly peripheral distribution 
consistent with expression in the podocytes 
in both control and diabetic rat kidneys. 
Fewer autoradiographic grains were detected 
in glomeruli from diabetic rats at 24 weeks 
and diabetic rats treated with 
aminoguanidine at 24 weeks than in the 
control animals, consistent with the 
quantitative TaqMan RT-PCR results. 
5.1.2.2 Expression at the protein level 
As seen by light microscopy in study 
II, immunohistochemical staining for 
nephrin in control animals revealed an 
epithelial-like pattern in glomeruli, with 
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clear reactivity in cells facing the urinary 
space, whereas the innermost glomerular tuft 
areas remained unstained (Study II, Figure 
7A). After 8 and 12 weeks of STZ induction, 
the overall intensity of nephrin staining was 
higher, and altered nephrin localization was 
observed. Typically a more central 
localization and nephrin staining deposits 
closer to the capillaries were observed in the 
STZ treated rats (Study II, Figure 7B). 
 
Figure 5.1. Nephrin mRNA changes in streptozotocin-treated rats. The data represented in the 
figure are combined from studies II and III. Values shown are means ± SEM relative to controls, 
which were assigned an arbitrary value of 1. The darkened bars show groups treated with either 
aminoguanidine (AG) or perindopril (PP). *P<0.05 versus control. **P<0.01 versus the 24 weeks 
diabetic group. At the time of model induction, the rats were 12 (study II) or 13 (study III) weeks 
of age. 
5.2 Urinary nephrin 
In study I, the immunoblotting of 
proteinuric stage urine samples at 6 and 10 
days from rats treated with puromycin 
aminonucleoside revealed a band of ~166 
kDa. No nephrin-specific bands could be 
observed in the day 0 and day 3 urine 
samples of low proteinuria in the PAN 
model (Study I, Figure 4). Immunoblots of 
the urine of STZ rats in study II detected a 
nephrin-specific band of ≤185 kDa in 
samples gathered at 4 to 6 weeks after model 
induction (Study II, Figure 4). 
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5.3 Nephrin autoantibodies 
5.3.1 Clinical and immunological profile of 
patients 
Comparison of the baseline clinical 
data of the type 1 diabetic patients at 
diagnosis including age, gender, blood 
pressure, creatinine levels, blood glucose, 
glycated hemoglobin levels, blood pH, 
presence of ketoacidosis, C-peptide levels or 
initial insulin dose categorized by the 
presence of nephrin autoantibodies revealed 
no significant differences (Study IV, Table 
1). A similar comparison between the 
respective patient characteristics categorized 
by the appearance of a sign of diabetic 
nephropathy during the follow-up period did 
not reveal any statistically significant 
differences either. During the follow-up 
period of up to 19 years, 11/66 (16.7%) had 
developed microalbuminuria and 3/66 
(4.5%) had progressed to overt proteinuria. 
In those patients the mean duration of 
diabetes at the manifestation of 
microalbuminuria and proteinuria was 9.5 
and 12.0 years, respectively. However, the 
time from diagnosis of diabetes to 
appearance of microalbuminuria/proteinuria 
varied considerably, with the first patient 
presenting with microalbuminuria already at 
2 years after diagnosis (Study IV, Figure 1). 
In tests to determine the correlation between 
the antibody levels and the ICA level in 
respective samples we noted that nephrin 
autoantibody levels did not correlate with 
ICA levels, unlike the IA-2A and GADA 
levels did. Interestingly, patients presenting 
with nephrin autoantibodies had always a 
HLA-DR4 and/or HLA-DR3 antigen present 
as well (Study IV, Table 3). 
5.3.2 Autoantibodies to nephrin 
At the time of diagnosis 16/66 
(24.2%) patients were positive for nephrin 
antibodies. These proportions were 14/61 
(23.0%), 8/58 (13.8%) and 8/44 (18.2%), 
respectively at 2, 5 and 10 years (Study IV, 
Table 2). Altogether 29/66 (43.9%) patients 
tested positive for nephrin autoantibodies in 
at least one sample. Substantial fluctuation 
was seen in the levels of nephrin antibodies 
over the 10-year measurement period, and 
the analysis of consecutive nephrin 
autoantibody levels within-subjects excluded 
any significant correlation (P=0.14). 
Similarly, the comparison between subject 
groups defined by the appearance of diabetic 
nephropathy (P=0.39) showed no difference 
among the nephrin autoantibody level 
profiles. Only 4/66 (6.1%) patients were 
positive in all measured samples. 
5.3.3 Nephrin autoantibodies and renal 
injury 
Among the patients with signs of 
renal injury (microalbuminuria or 
proteinuria), 4/14 (28.6%) were positive for 
nephrin autoantibodies on at least one 
occasion. The respective proportion among 
the patients without a sign of renal 
complication was 25/52 (48.1%). In the 
subgroup of patients with renal injury and 
nephrin autoantibodies detected in at least 
one sample the mean duration of diabetes at 
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manifestation of microalbuminuria was 7.7 
years, with a 95% confidence interval (CI) 
between 0.0 to 20.4 years. The patients free 
of nephrin autoantibodies had a later 
manifestation of microalbuminuria at a mean 
of 10.1 years (95% CI 7.0 to 13.2 years). 
However, the observed mean difference of 
2.4 years is statistically insignificant 
(P=0.42). 
5.3.4 Immunofluorescence 
Immunohistochemical stainings of rat 
kidney cortex sections were done using the 
three diabetic serum samples with highest 
levels of nephrin autoantibodies. This 
revealed an epithelial-type glomerular 
staining typical for nephrin with two of the 
sera. One patient serum sample showed 
negligible reactivity, as did the stainings 
with negative control sera and secondary 
antibodies alone (Study IV, Figure 2). 
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6 DISCUSSION 
6.1 Nephrin and podocyte in proteinuric conditions 
In studies I-III it was shown that 
under conditions of proteinuria and podocyte 
injury, the mRNA and protein expression 
levels of nephrin are altered. Our work was 
done in animals using the rat PAN and STZ 
models as well as NOD mice. 
In our study with the PAN model, 
nephrin-alpha mRNA levels were shown to 
decrease. Puromycin aminonucleoside given 
as a single dose is toxic to the podocyte as 
reviewed earlier in chapter 2.4.1. 
Importantly, in the PAN model the 
podocytes and kidneys as a whole recover 
from the toxic insult (Ryan GB et al., 1975). 
Permanent podocyte loss doesn’t seem to 
take place, while podocyte foot processes 
are temporarily detached (Messina A et al., 
1987). This, and the in vitro data showing a 
decrease in the expression of α3β1-integrin 
in the podocytes (Krishnamurti U et al., 
2001), suggests that the nephrin-alpha 
mRNA and nephrin mRNA level decreases 
seen in study I could at least partly be an 
actual sign of decreased production of the 
protein rather than a sign of massive 
podocyte death. In opposition to this 
interpretation are the in vitro results 
implicating also apoptosis in the detachment 
process (Suzuki T et al., 2001). However, 
podocytes are believed to be incapable of 
cell replication (Kriz W et al., 1998) and a 
massive podocyte loss in PAN model is not 
a typical feature seen in electron 
microscopic studies (Messina A et al., 
1987). Accordingly, Suzuki and colleagues 
conclude in their article that apoptosis may 
only partly explain the detachment. 
In studies II and III, kidney samples 
from experimental animals with long-
standing proteinuria due to diabetic 
nephropathy showed a clear reduction in 
nephrin mRNA expression. This reduction in 
nephrin expression in association with long-
standing proteinuria is confirmed by several 
other experimental studies (Forbes JM et al., 
2002; Davis BJ et al., 2003; Cohen MP et 
al., 2005; Ichinose K et al., 2005). Nephrin 
mRNA expression is seen to decrease in 
human diabetic nephropathy as well 
(Langham RG et al., 2002; Toyoda M et al., 
2004). However, the exact mechanisms 
behind this observed reduction in nephrin 
are not clear. In the kidney tissue, nephrin is 
specifically located in the podocytes. 
Therefore, nephrin also parallels the amount 
of podocytes in a given sample of kidney 
tissue. Since the podocytes can alter their 
gene expression levels of nephrin, as 
demonstrated by the PAN model used in 
study I, direct conclusions between nephrin 
mRNA amount and podocyte count in 
different samples and time points can be 
misleading. Nevertheless, in a condition 
with an abnormally permeable glomerular 
filtration system, it would seem 
contradictory that nephrin, a crucial 
component of the slit diaphragm, was 
physiologically downregulated. Instead, as 
was observed in study II, at the initial phases 
of diabetic nephropathy nephrin mRNA 
expression actually increased (Figure 5.1). 
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This was later confirmed by Forbes et al. 
(Forbes JM et al., 2002). Furthermore, the 
commonly acknowledged increase in PKC 
activity during diabetic nephropathy in the 
podocyte, as described in the literature 
review in chapter 2.5, seems to rather 
increase than decrease nephrin expression 
(Wang SX et al., 2001b). The genotoxic 
effects of STZ on the kidney should have 
been repaired already by the sample time 
points of 4 and 8 weeks in our study, as 
reviewed earlier in chapter 2.4. However, it 
is clear that preneoplastic or even neoplastic 
cells will prevail in the kidneys of STZ 
treated rats throughout their life, possibly 
causing some confounding results in longer-
term studies using test compounds giving 
further tumor-promoting stimuli. As also 
shown by our results in study III, treatment 
with perindopril, an ACE inhibitor, appears 
to prevent the decrease of nephrin 
expression in STZ rats. Remarkably, another 
anti-proteinuric treatment with 
aminoguanidine, a drug reducing the 
formation of AGEs, did not prevent this drop 
in nephrin expression (Figure 5.1). Both 
treatments could reduce proteinuria, 
although it must be stressed, that the systolic 
blood pressure was clearly higher in the 
aminoguanidine –treated group as compared 
to the perindopril –treated group (Study III, 
Table 2). The adverse effect of high blood 
pressure was therefore an additional burden 
for the glomerular filtration barrier in the 
aminoguanidine treated STZ rats. In another 
study in STZ diabetic rats, the angiotensin II 
receptor type 1 antagonist valsartan 
conferred protection from reduced nephrin 
expression, while an equally hypotensive 
regimen with the calcium channel blocker 
amlodipine did not prevent the reduction 
(Davis BJ et al., 2003). The mechanism 
protecting from the decrease in nephrin 
mRNA expression levels appears to be 
related to RAS inhibition. 
As is the case for STZ genotoxicity in 
kidney, it is unlikely that the absence of a 
delay before starting the treatment as 
suggested by Kraynak et al. (Kraynak AR et 
al., 1995) has affected our results of 
renoprotection in study III. First of all, in a 
very early sample at 1 week after STZ 
injection there was no change in nephrin 
mRNA expression (Figure 5.1), suggesting 
that podocytes or at least their nephrin 
expression is not significantly disturbed by 
DNA damage caused by STZ. Second, 
neither perindopril nor aminoguanidine are 
known to have significant tumor-promoting 
effects. On the contrary, perindopril is 
considered to be antiangiogenic and may 
even have potential for cancer therapies 
(Yoshiji H et al., 2002). In any case, these 
results suggest that treatment with RAS 
inhibitors may involve mechanisms in the 
podocyte which contribute to the survival of 
the podocyte as suggested by the retained 
normal expression levels of nephrin mRNA. 
Moreover, the ability of the podocyte to 
keep the filtration slit diaphragm functional 
seems to involve complex signalling in 
which nephrin is clearly implicated. 
Nephrin-dependent signalling is also 
shown to be important for the podocyte to 
avoid apoptosis, induced e.g. by detachment 
of the podocyte from the GBM (Huber TB et 
al., 2003a). The lipid rafts that collect the 
important signalling proteins at the slit 
diaphragm can be disrupted during podocyte 
injury, leading to dislocation of these 
proteins to the apical part of the podocyte 
foot process cell membrane (Simons M et 
al., 2001). This loss of functional nephrin 
could lead to increased apoptosis due to loss 
of nephrin-signalling (see Figure 2.6.2). The 
podocyte could therefore be argued to be 
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forced to increase its expression of nephrin 
mRNA to compensate for this loss of 
functional nephrin. 
Patients with type 1 diabetes show 
reduced counts of podocytes (Steffes MW et 
al., 2001) and in diabetic nephropathy 
podocytes appear to be shed into the urine. 
First, we detected nephrin protein in urine of 
diabetic rats by immunoblotting in study II. 
The approximate molecular weight of the 
urinary nephrin band blotted study II 
corresponds with the glomerular nephrin. 
Nephrin or fragments of nephrin are also 
detected in the urine of patients with type 1 
diabetes (Pätäri A et al., 2003). Second, 
apical membrane fragments of podocytes 
with intact podocalyxin have been detected 
in the urine of patients with proteinuria 
(Hara M et al., 2005). Most convincingly, 
whole viable podocytes can be recovered 
from the urine in a model of diabetic 
nephropathy (Petermann AT et al., 2004). 
The evident loss of podocytes into the urine 
directly means also loss of nephrin protein 
on the membrane surfaces of these cells as 
well as loss of nephrin mRNA within their 
cytoplasm. Furthermore, the fact that 
podocytes are capable to avoid detachment-
induced apoptosis in diabetic nephropathy 
shows that there must also be efficient anti-
apoptotic signalling factors present. 
Nephrin-signalling is shown to be such a 
factor in the podocyte, and functional 
nephrin at the correct cell membrane domain 
is required for this signalling to take place 
(Huber TB et al., 2005). Podocyte survival 
would be compromised if nephrin 
expression in the podocyte was significantly 
reduced. 
Taking all this together, a combined 
model for podocyte nephrin expression 
levels seen in diabetic nephropathy is here 
proposed. As mentioned above, the 
pathologic signalling changes and leaky 
glomerular filtration slit are suggested to 
increase rather than decrease the nephrin 
expression in the podocyte as a 
compensatory mechanism. At the initial 
stages of diabetic nephropathy the increased 
protein permeability of the filtration system 
is proposed to mainly be due to increased 
VEGF and its effects on the endothelium 
(Schrijvers BF et al., 2004). At this point, 
hyperglycaemic conditions increase PKC 
signalling in the podocytes, nephrin mRNA 
expression is seen to be increased, and in 
immunohistochemisty dislocation of nephrin 
protein expression to more central parts of 
the podocytes can be seen along with the 
overall increase in nephrin protein 
expression levels (Study II, Figure 7B). 
Later, during the development of 
diabetic nephropathy, glomerular scarring 
and thickening of the GBM are 
histologically visible. At this stage, since 
scarring is seen, a significant number of 
podocytes must have been lost. The 
currently proposed interpretation of the 
results suggests that the nephrin mRNA 
decrease seen in many studies largely 
reflects the mass loss of podocytes. 
Expression of nephrin in single podocytes 
during diabetic nephropathy may be normal 
or even increased as at the initial stages of 
the pathologic process. Thus, a decrease in 
nephrin mRNA could be considered as a 
crude indicator of podocyte count in subjects 
with diabetic nephropathy. This can be 
argued because the methodological 
limitations of the PCR techniques must be 
taken into account. Genes used to normalize 
the expression levels between samples 
known to be expressed with constant levels 
in a given condition are called housekeeping 
genes. In the kidney the housekeeping genes 
used in the above mentioned expression 
 56 
studies, including our own work, are 
expressed in virtually all cells present in the 
cortical kidney tissue. Since the total cell 
mass and, along with this, the total 
housekeeping gene expression in the kidneys 
is only minimally decreased due to podocyte 
loss, the determination of expression levels 
of a given gene specifically in a podocyte 
would require further research with 
application of single-cell PCR methods on 
isolated podocytes. Another approach to 
tackle this question could be to normalize 
the measured nephrin mRNA levels to some 
podocyte-specific housekeeping gene, i.e. a 
gene with known constant expression level. 
Currently, such gene is unfortunately not 
known. Also isolation of glomeruli can be 
used to enhance the accuracy of nephrin 
mRNA quantifications normalized with 
commonly expressed housekeeping gene 
mRNA levels. In line with the present 
interpretation, is has been shown that in 
various acquired kidney diseases nephrin 
protein levels visualized by 
immunohistochemistry are reduced whereas 
the glomerular mRNA levels of nephrin are 
increased (Koop K et al., 2003), possibly 
also representing an increased turn-over rate 
of nephrin protein product. 
 
6.2 Immunological aspects of diabetic nephropathy 
In study IV, circulating 
autoantibodies to nephrin were found in 
patients with type 1 diabetes. Glomeruli 
could also be stained in an epithelial-like 
pattern with patient sera of the highest 
nephrin autoantibody levels. 
The first indicator of autoantibody 
generation in type 1 diabetes was the 
discovery of circulating antibodies against 
the islets of Langerhans (Bottazzo GF et al., 
1974), now known to comprise antibodies to 
a heterogeneous set of islet cell antigens, 
such as insulin, glutamic acid decarboxylase 
(GAD) and IA-2 (Palmer JP et al., 1983; 
Baekkeskov S et al., 1990; Lan MS et al., 
1996). The presence of these autoantibodies 
is associated with the early preclinical phase 
of type 1 diabetes. It is known that at least 
either one of GADA or IA-2A is present in 
more than 90% of patients with recent onset 
type 1 diabetes (Savola K et al., 1998). The 
nephrin autoantibody prevalence profile 
during the sampling period over the 10 first 
years of type 1 diabetes is similarly 
declining as the prevalence profile of the 
ICA, IA-2A or GADA. This suggests also 
that the nephrin autoantibodies are generated 
during the autoimmune process leading to 
type 1 diabetes. In any case, our result 
indicates that nephrin can act as an 
autoantigen in patients with type 1 diabetes. 
However, nephrin autoantibodies have a low 
prevalence at the time of diagnosis of 
clinical diabetes (Study IV, Table 2) and 
thus may not function as clinical markers of 
the disease process of diabetes itself. 
Approximately one third of patients 
with type 1 diabetes develop diabetic 
nephropathy during the course of their 
disease (Rossing P et al., 1995). Some 
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patients experience a rapidly progressive 
glomerular injury, while others develop this 
complication only after decades. 
Accordingly, diabetic nephropathy seems to 
be a multifactorial disease. In 1993 it was 
for the first time shown that an intervention 
with ACE inhibitors could postpone diabetic 
nephropathy (Lewis EJ et al., 1993). 
However, it should be noted that even ACE 
inhibition is not capable in curing or 
completely preventing diabetic nephropathy. 
ACE inhibition is a routine treatment, 
although it is also associated with potential 
side effects. This emphasizes the importance 
of accurate early diagnostics to identify 
patients benefiting from intensive therapy. In 
an attempt to meet the needs of early 
diagnosis, microalbuminuria has been used 
as a marker for diabetic nephropathy 
(Mogensen CE et al., 1984). However, 
approximately 7% of nondiabetic, 
nonhypertensive subjects present with 
microalbuminuria as well (Tomura S et al., 
1999; Hillege HL et al., 2001). Moreover, 
not all diabetic patients with 
microalbuminuria develop overt 
nephropathy and, furthermore, clear 
histopathological changes can develop 
without long-standing microalbuminuria 
(Chavers BM et al., 1989; Fioretto P et al., 
1994). Taken together these facts call for 
novel early molecular markers of diabetic 
nephropathy (Caramori ML et al., 2000). To 
explore the potential of nephrin 
autoantibodies as such a marker we 
hypothesized that circulating nephrin 
autoantibodies partly explain diabetic 
damage of the glomerular filtration barrier. 
This hypothesis was founded on the facts 
that in vivo injected (Orikasa M et al., 1988; 
Topham PS et al., 1999) or naturally 
occurring antinephrin antibodies (Wang SX 
et al., 2001a; Patrakka J et al., 2002) cause 
glomerular damage and proteinuria. 
Type 1 diabetic patients developing 
kidney complications, as indicated by the 
appearance of microalbuminuria or 
proteinuria, and those remaining unaffected 
present with statistically indifferent nephrin 
autoantibody proportions. During the 
follow-up period, only 4/29 (13.8%) patients 
positive for nephrin autoantibodies at any 
time point developed microalbuminuria or 
overt proteinuria. It is therefore unlikely that 
the nephrin autoantibodies significantly 
affect the development of diabetic 
nephropathy. Our test screened the samples 
mainly for autoantibodies against epitopes of 
the intracellular part of nephrin. In addition 
to covering one third of the extracellular 
part, we chose to cover the whole 
intracellular portion with our labeled nephrin 
probe. This was done, since the intracellular 
part is normally “hidden” from immune 
surveillance and immunotolerance. During 
the autoimmune process in the islets of 
Langerhans, nephrin autoantibodies were 
most likely to be generated by the process 
known as epitope spreading. The process of 
epitope spreading results from secondary 
endogenous priming with new self-antigens, 
after the primary generation of an immune 
response to disease-initiating self-antigens. 
It has been demonstrated that progression in 
autoimmune disease involves shifting of 
autoreactivity from primary initiating self-
determinants to defined cascades of 
secondary determinants (Tuohy VK et al., 
1999). Such epitope spreading occurs also in 
the autoimmune response to GAD during the 
preclinical stages of type 1 diabetes 
(Sohnlein P et al., 2000). Studies on T cell 
epitope spreading suggest that once the 
CD4+ T cell tolerance is broken for one 
epitope, the autoimmune response can 
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spread to other epitopes within the same 
autoantigen and even to nearby autoantigens 
(Lehmann PV et al., 1992; Miller SD et al., 
1995). The autoimmune response in type 1 
diabetes leads to beta cell damage, which 
may then lead to the exposure of hidden 
cytoplasmic epitopes rendering them 
available to an autoimmune attack. Due to 
these factors, to screen for nephrin 
autoantibodies in type 1 diabetes using 
mainly an intracellular epitope probe seemed 
to be the rational approach. 
One explanation for the absence of 
significant damage to the kidneys could be 
that the intracellular nephrin epitopes are 
protected in the podocyte cytoplasm. 
Formation of linear deposits of IgG in the 
diabetic glomeruli has been reported earlier 
(Mauer SM et al., 1972; Axe SR et al., 
1981). Although fluctuation in the individual 
nephrin autoantibody titers was seen in the 
present study, the subset of patients with 
constantly prevailing nephrin antibodies may 
increasingly accumulate these antibodies in 
the kidney. The pathogenicity of such IgG 
deposits in diabetic nephropathy remains 
unknown. It must also be stated, that the 
follow-up study was not originally designed 
to find out whether circulating 
autoantibodies could end up in the kidney 
glomerulus and attach to their respective 
epitopes. The immunohistochemical 
stainings with patient sera did not exclude 
this possibility, but the issue requires further 
study. 
6.3 Conclusions 
In conclusion, this thesis work could 
show changes of nephrin expression along 
with the development of proteinuria. In the 
PAN model, the nephrin-alpha and full-
length nephrin expression levels appeared to 
decrease. In the initial stages of diabetic 
nephropathy, nephrin expression levels 
appear to increase. Later, in overt 
nephropathy, a decrease in nephrin mRNA 
expression could be seen, probably 
reflecting a declining amount of intact 
podocytes. 
It was also shown that a subset of 
patients with type 1 diabetes have circulating 
autoantibodies to nephrin. These 
autoantibodies are most likely to be 
generated in the autoimmune process 
leading to type 1 diabetes. However, it is 
unlikely that the nephrin autoantibodies 
detected are significantly contributing to the 
development of diabetic nephropathy. 
Further research is needed to fully resolve 
the prognostic potential of such 
autoantibodies. 
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